Pr ot oc ol : J 2 Z- M C- P G A A  (c) 
A P hase 1, Ra n d o mize d, Place b o- C o ntr olle d St u d y t o E val uate t he T olera bilit y, Safet y, 
P har mac o ki netics, a n d I m m u n o ge nicit y of L Y 3 8 3 2 4 7 9 Gi ve n as a Si n gle I ntra ve n o us D ose i n 
Healt h y Partici pa nts 
N C T 0 4 4 4 1 9 3 1   
A p pr o val Date: 1 5-J ul- 2 0 2 0 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
1Title P a ge 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s. It i s t h e pr o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al 
i n v e sti g ati o n of L Y 3 8 3 2 4 7 9 , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d C o m p a n y or it s 
s u b si di ari e s. 
N ot e t o R e g ul at or y A ut h oriti e s: T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n 
e x e m pt fr o m p u bli c di s cl o s ur e. Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e. 
I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or 
ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s .
Pr ot oc ol Title: A P hase 1, Ra n d o mi ze d, Pl ace b o -C o ntr olle d St u d y  t o E val uate t he T olera bilit y,  
S af et y,  P har m ac o ki netics, a n d I m m u n o ge nicit y of L Y 3 8 3 2 4 7 9 Gi ve n as a Si n gle 
I ntra ve n o us D ose i n Healt h y Partici pa nts 
Pr ot oc ol N u m ber: J 2 Z -M C -P G A A 
A me n d me nt N u m ber: c
C o m p o u n d :L Y 3 8 3 2 4 7 9 
St u d y P h ase: 1
S h ort Title: A P hase 1, Ra n d o mize d, Place b o -C o ntr olle d St u d y  t o E val uate L Y 3 8 3 2 4 7 9 i n 
Heal t h y Parti ci pa nts 
S p o ns or N a me: El i Lill y  a n d C o m pa n y 
Le g al Re gistere d A d dress: I n dia na p olis, I n dia na U S A 4 6 2 8 5 
Re g ul at or y A ge nc y I de ntifier N u m ber(s) 
Pre -I N D n u m ber : 1 5 0 7 0 7 
A p pr o v al D ate: Pr ot oc ol El ectr o nicall y Si g ne d a n d A p pr o ve d b y Lill y o n t h e date pr o vi de d 
bel o w. 
A p pr o v al D at e: 1 5- J ul- 2 0 2 0 G M T 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Original Protocol 03-Jun-2020
Amendment (a) 23-Jun-2020
Amendment (b) 26-Jun-2020
Amendment (c)
Overall Rationale for the Amendment:
Language has been added throughout the protocol t o allow for collect ion of additional swab 
samples ,some of which may be used for research purposes. 
Section # and 
NameDescription of Change Brief Rationale
Secti on 1. 3 
(Schedule of 
Activities); 
Secti on 5.1
(Inclusion 
Criteria)Added reference to post-
baseline nasal or 
nasopharyngeal swab . To facilitate analysis o f postbaseline 
samples for research purposes .
Secti on 8.3.7 , 
(SARS -Cov-2 
Infection );
Secti on 8.8 
(Biomarkers)Added descript ion of how 
and when post-baseline nasal 
or nasopharyngeal swab will 
be admi nistered .As above.
Secti on 10.2 
(Appendix 2: 
Clinical 
Laboratory  Tests)Added detail o f how post-
baseline nasal or 
nasopharyngeal sample will 
be managed .As above.
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
4T a ble of C o nte nts 
1. Pr ot oc ol S u m m ar y ...................................................................................................... 7
1. 1. S y n o psis ....................................................................................................................... 7
1. 2. Sc he ma ......................................................................................................................... 8
1. 3. Sc he d ule of Act i v it ies ( S o A) ........................................................................................ 9
2. I ntr o d ucti o n .............................................................................................................. 1 5 
2. 1. St u d y  Rati o nale .......................................................................................................... 1 5 
2. 2. Bac k gr o u n d ................................................................................................................ 1 5 
2. 3. Be nefit/ Ris k Assess me nt ............................................................................................ 1 5 
3. O bjecti ves a n d E n d p oi nts ......................................................................................... 1 8 
4. St u d y Desi g n ............................................................................................................. 1 9 
4. 1. O verall Desi g n............................................................................................................ 1 9 
4. 1. 1. Si n gle -Asce n di n g D ose Desi g n ................................................................................... 1 9 
4. 2. S ci e nt ific Rati o nale f or St u d y  Desi g n ......................................................................... 2 0 
4. 3. J ust ificati o n f or D ose .................................................................................................. 2 0 
4. 4. E n d of St u d y  Defi nit i o n.............................................................................................. 2 2 
5. St u d y P o p ul ati o n ...................................................................................................... 2 3 
5. 1. I ncl usi o n Cri t eri a........................................................................................................ 2 3 
5. 2. E xcl u si o n  Cri t eri a....................................................................................................... 2 3 
5. 3. Lifest yle C o nsi derat i o ns ............................................................................................. 2 6 
5. 3. 1. Meals a n d Dietar y  Restri ct i o ns ................................................................................... 2 6 
5. 3. 2. Caffei ne, Alc o h o l,  a n d T o bacc o .................................................................................. 2 6 
5. 3. 3. Act i vit y...................................................................................................................... 2 6 
5. 4. Scree n Fail ures ........................................................................................................... 2 6 
6. St u d y I nter ve nti o n .................................................................................................... 2 7 
6. 1. St u d y  I nter ve nt i o ns A d mi nistere d ............................................................................... 2 7 
6. 1. 1. I nf usi o ns ..................................................................................................................... 2 8 
6. 2. Pre parati o n/ Ha n dli n g/ St ora ge/ Acc o u nta bilit y............................................................. 3 0 
6. 3. Meas ures t o Mi ni mize Bias: Ra n d o mizat i o n a n d Bli n di n g .......................................... 3 0 
6. 4. St u d y  I nter ve nt i o n C o m plia nce ................................................................................... 3 1 
6. 5. C o nc o mita nt T hera p y ................................................................................................ . 3 1 
6. 6. D ose M o dificat i o n...................................................................................................... 3 1 
6. 6. 1. D ose -Escal at i o n Cri t eri a............................................................................................. 3 1 
6. 6. 2. Access t o Data d uri n g t he St u d y ................................................................................. 3 2 
6. 6. 3. T e m p orar y  St o p pi n g Cri t eri a...................................................................................... 3 2 
6. 7. I nter ve nti o n after t he E n d of t he St u d y ........................................................................ 3 2 
7. Disc o nti n u ati o n of St u d y I nter ve nti o n a n d P artici p a nt 
Disc o nti n u ati o n/ Wit h dr a w al .................................................................................... 3 3 
7. 1. Di sc o nti n uati o n of  St u d y  I nter ve nt i o n........................................................................ 3 3 
7. 2. P arti ci pa nt Disc o nti n uati o n/ Wit h dra wal fr o m t h e St u d y ............................................. 3 3 
7. 2. 1. Di sc o nti n uati o n of  I na d verte nt l y E nr olle d Partici pa nts ............................................... 3 3 
7. 3. L ost t o F oll o w - u p ....................................................................................................... 3 4 
8. St u d y A ssess me nts a n d Pr oce d ures ......................................................................... 3 5 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
58. 1. Efficac y Assess me nts ................................................................................................ . 3 5 
8. 2. S af et y Assess me nts .................................................................................................... 3 5 
8. 2. 1. Vi tal  Si g ns.................................................................................................................. 3 5 
8. 2. 2. Electr ocar di o gra ms ..................................................................................................... 3 5 
8. 2. 3. Cli nical Safet y  L a b orat or y  A ssess me nts ..................................................................... 3 6 
8. 2. 4. He pati c M o ni t ori n g ..................................................................................................... 3 6 
8. 3. A d verse E ve nts a n d Seri o us A d verse E ve nts .............................................................. 3 8 
8. 3. 1. Ti me Peri o d a n d Fre q ue nc y  f or C ollect i n g A E a n d S A E 
I nf or m at i o n................................................................................................................. 3 8 
8. 3. 2. Met h o d of Detecti n g A Es a n d S A Es ........................................................................... 3 9 
8. 3. 3. F o ll o w- u p of  A Es a n d S A Es ....................................................................................... 3 9 
8. 3. 4. Re g ulat or y  Re p orti n g Re q uire me nts f or S A Es ............................................................ 3 9 
8. 3. 5. Pre g na nc y ................................................................................................................... 3 9 
8. 3. 6. H y perse nsi ti vi t y  R e a cti o ns ......................................................................................... 4 0 
8. 3. 7. S A R S -C O V -2 I nfect i o n.............................................................................................. 4 0 
8. 3. 8. I nf usi o n- Relate d Reacti o ns ......................................................................................... 4 1 
8. 3. 9. Pr o d uct C o m plai nt s.................................................................................................... 4 1 
8. 4. Treat me nt of O ver d ose ............................................................................................... 4 2 
8. 5. P har mac o ki net ics ........................................................................................................ 4 2 
8. 6. P har mac o d y na mics ..................................................................................................... 4 2 
8. 7. Ge net ic s..................................................................................................................... 4 2 
8. 8. Bi o m ar kers ................................................................................................................. 4 2 
8. 9. I m m u n o ge nicit y Assess me nts ..................................................................................... 4 3 
8. 1 0. Heal t h  Ec o n o mics ....................................................................................................... 4 3 
9. St atistic al C o nsi der ati o ns ......................................................................................... 4 4 
9. 1. Stati st ical H y p ot heses ................................................................................................ . 4 4 
9. 2. S a m ple Si ze Deter mi nat i o n......................................................................................... 4 4 
9. 3. P o p ul at i o ns f o r A nal yses ............................................................................................ 4 4 
9. 4. Stati st ical A nal yses ..................................................................................................... 4 4 
9. 4. 1. Ge neral C o nsi derati o ns ............................................................................................... 4 5 
9. 4. 2. Pri mar y E n d p o i nt s ( Safet y) ......................................................................................... 4 5 
9. 4. 3. Sec o n dar y  E n d p o i nt s ( P K) .......................................................................................... 4 5 
9. 4. 4. Terti ar y/ E x pl orat or y  E n d p o i nt  (I m m u n o ge nicit y) ....................................................... 4 5 
9. 4. 5. Ot her A nal yses ........................................................................................................... 4 6 
9. 5. I nteri m A nal yses ......................................................................................................... 4 6 
1 0. S u p p orti n g D oc u me nt ati o n a n d O per ati o n al C o nsi der ati o ns ................................ 4 7 
1 0. 1. A p pe n di x 1: Re g ulat or y , Et hical , a n d St u d y  O versi g ht 
C o nsi derati o ns ............................................................................................................ 4 7 
1 0. 1. 1. Re g ulat or y  a n d Et hi cal  C o nsi derat i o ns ........................................................................ 4 7 
1 0. 1. 2. I nf or m e d C o nse nt Pr ocess .......................................................................................... 4 7 
1 0. 1. 3. Data Pr otecti o n ........................................................................................................... 4 8 
1 0. 1. 4. Di sse mi nat i o n of Cli nical St u d y  Data ......................................................................... 4 8 
1 0. 1. 5. Data Q ualit y Ass ura nce .............................................................................................. 4 8 
1 0. 1. 6. S o urce D oc u me nts ...................................................................................................... 5 0 
1 0. 1. 7. St u d y  a n d Si te Start a n d Cl os ure ................................................................................. 5 0 
1 0. 1. 8. P u blicat i o n P olic y ....................................................................................................... 5 1 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
61 0. 1. 9. I n vest i gat or I nf or mat i o n............................................................................................. 5 1 
1 0. 1. 1 0. L o n g -Ter m  Sa m ple Rete nt i o n..................................................................................... 5 1 
1 0. 2. A p pe n di x 2: Cli nical La b orat or y  Tests ........................................................................ 5 2 
1 0. 2. 1. Bl o o d S a m pli n g S u m mar y .......................................................................................... 5 5 
1 0 . 3. A p pe n di x 3: A d verse E ve nts: Defi nit i o ns a n d Pr oce d ures f or 
Rec or di n g, E val uat i n g, F oll o w -u p, a n d Re p orti n g ....................................................... 5 6 
1 0. 3. 1. Defi nit i o nof  A E ......................................................................................................... 5 6 
1 0. 3. 2. Defi nit i o n o f S A E ....................................................................................................... 5 7 
1 0. 3. 3. Rec or di n g a n d F o ll o w- U p of A E a n d/ or S A E ............................................................. 5 8 
1 0. 3. 4. Re p orti n g of S A Es ...................................................................................................... 5 9 
1 0. 4. A p pe n di x 4: C o ntrace pti ve G ui da nce a n d C o llect i o n of 
Pre g na nc y I nf or mati o n ............................................................................................... 6 1 
1 0. 4. 1. W o me n....................................................................................................................... 6 1 
1 0. 4. 2. Me n ............................................................................................................................ 6 1 
1 0. 4. 3. C ollect i o n of Pre g na nc y  I nf or m at i o n.......................................................................... 6 2 
1 0. 5. A p pe n di x 5: Ge netics ................................................................................................ . 6 4 
1 0. 6. A p pe n di x 6:  Li ver Safet y:  S u g geste d Acti o ns a n d F oll o w -U p 
Assess me nts ............................................................................................................... 6 5 
1 0. 7. A p pe n di x 7: Rec o m me n de d La b orat or y Test i n g f o r 
H y perse nsi ti vi t y  E ve nts .............................................................................................. 6 7 
1 0. 8. A p pe n di x 8: A b bre viat i o ns ......................................................................................... 6 9 
1 1 . Refere nces ................................................................................................................. 7 2 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
71. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase 1, Rando mized, Placebo -Controlled Study  to Evaluate the Tolerabilit y, 
Safety, Pharmacokinetics, and Immunogenicit y of LY3832479 Given as a Single Intravenous 
Dose in Healt hy Part icipants
Short Title: A Phase 1, Rando mized, Placebo -Controlled Study  to Eval uate LY3832479 in 
Healthy Parti cipants
Rationale :
Lilly is developing LY3832479 for the treatment and prevention of coronavi rus disease 2019
(COVID -19). Study J2Z-MC-PGAA (PGAA) will investigate the safet y, tolerabilit y, and 
pharmacokinet icsof LY3832479 when administered as a single intravenous dose to healthy 
participants.
Objectives and Endpoint s
Object ives Endpoints
Primary
To investigate the safet y and 
tolerabilit y of a single dose of 
LY3832479 in healt hy part icipantsSerious and nonserious adverse events, 
laboratory  measures of safet y, ECG, 
and vital signs
Secondary
To characterize the pharmacokinetics 
of LY3832479 following a single IV
administration of LY3832479 to 
healt hy participantsAUC, Cm ax
Abbreviations: AUC = area under the concentration versus time curve; Cmax = maximum observed drug 
concentration; ECG = electrocardiogram; IV = intravenous.
Overall Design
Study  PGAA is a Phase 1, randomized, placebo -controlled study ofLY3832479 administered to
healt hy participants.
The study  will com prise up to 3 cohorts, each with an intended number of participants as 
follows:
Cohorts 1 and 2
At least 9 participants :
7 randomized to LY3832479 and
2 randomized to placebo.
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
8C o h ort 3 
At  least 8 partici pa nts :
6 ra n d o mize d t o L Y 3 8 3 2 4 7 9 a n d 
2 ra n d o mize d t o place b o. 
P arti ci pa nts will be i nit iall y  m o ni t or e d f or s af et y wit hi n t he st u d y  si t e w here t he y  will be 
a d mitte d o n Da y  - 1, d ose d o n Da y  1, di sc har ge d o n Da y  4, a n d s u bse q ue nt l y m o nit ore d o n a n 
o ut pati e nt basis u nt il t he last f o ll o w- u p visit .
Discl os ure St ate me nt : T hi s is a se q ue nt ia l, si n gle -asce n di n g d ose st u d y  wi t h  u p t o 3 c o h orts t hat 
is partici pa nt a n d i n vest i gat or bli n de d .
N u m ber of P artici p a nt s: 
A ma xi m u m of 3 0 partici pa nts will be e nr o lle d t o st u d y i nter ve nt i o n s uc h t hat a p pr o xi matel y 
8  parti ci pa nts ha ve s ufficie nt e val ua ble data i n eac h of  t he 3 c o h ort s. 
I nter ve nti o n Gr o u ps a n d D ur ati o n :
Si n gle -d ose st u d y  wi t h  a n est i mate d d urati o n f or eac h par tici pa nt of u p t o 1 6 wee ks fr o m 
scree ni n g t hr o u g h f o ll o w- u p. 
D at a M o nit ori n g C o m mittee: N o 
1. 2. Sc he m a 
A b bre viati o ns: L Y = L Y 3 8 3 2 4 7 9 ; P B O = place b o; P K = p har mac o ki netics. 
N ote: After at least 7 partici pa nts ha ve c o m plete d Da y 4 i n a gi ve n c o h ort, all safet y data u p t o t his c ut off date will 
be re vie we d t o deter mi ne w het her t he ne xt c o h ort ca n be e nr olle d after a gree me nt bet wee n Lill y’s me dical 
m o nit or a n d t he i n vesti gat or. 
Fi g ure 1. Si n gle -asce n di n g d ose sc he m a f or St u d y J 2 Z- M C -P G A A .C o h ort 2
7LY : 2 P B O
C o h ort 1
7LY : 2 P B OC o h ort 3
6LY : 2 P B O
D os e L ev el 1
( 7 0 0 m g of LY or P B O) D os e L ev el 2
( 2 8 0 0 m g of LY or P B O) D os e L ev el 3
( 7 0 0 0 m g of LY or P B O) 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
91. 3. Sc he d ule of Acti vities ( S o A) 
Pr oce d ure / 
Assess me nts Scree ni n g D osi n g P ost d ose F oll o w -u p Visits 
C o m me nt Visit N u m ber V 1 V 2 V 3  V 4 V 5  V 6  V 7  V 8  V 9 V 1 0/ 
E D 
Wee k(s) 0 1 2 3 4 6 8 1 0 1 2 
St u d y D a y - 1 4 
t o –2- 1 1 2 3 4 8 
± 1 d 1 5 
± 2 d 2 2 
± 2 d 2 9 
± 3 d 4 3 
± 3 d 5 7 
± 3 d 7 1 
± 3 d 8 5 
± 3 d 
I n f or me d c o nse nt 
( writte n) X
Re vie w/c o nfir m 
i ncl usi o n/e xcl usi o n 
criteria X  X Pre d ose After scree ni n g, e ns ure 
partici pa nts c o nti n ue t o 
meet I/ E criteria .
Me dical h ist or y 
i ncl u di n g pre -e xisti n g 
c o n diti o ns X
Wei g ht/ hei g ht X XHei g ht at scree ni n g 
o nl y .
Uri nal ysis X
C O VI D -1 9 cli nical 
scree ni n g X  X X  X  X  X  X  X  X  X S y m pt o ms a n d rece nt 
c o ntact (see Secti o n 
8. 3. 7 f or a descri pti o n 
of s y m pt o ms a n d cl ose 
c o ntact). At scree ni n g, 
Da y -1 a n d as nee de d 
d uri n g t he st u d y. See 
Secti o n 4. 1 f or details. 
S A R S -C o V -2 ser ol o g y X X X X XSer ol o g y res ults are n ot 
nee de d bef ore d osi n g. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
1 0 Pr oce d ure / 
Assess me nts Scree ni n g D osi n g P ost d ose F oll o w -u p Visits 
C o m me nt Visit N u m ber V 1 V 2 V 3  V 4 V 5  V 6  V 7  V 8  V 9 V 1 0/ 
E D 
Wee k(s) 0 1 2 3 4 6 8 1 0 1 2 
St u d y D a y - 1 4 
t o –2- 1 1 2 3 4 8 
± 1 d 1 5 
± 2 d 2 2 
± 2 d 2 9 
± 3 d 4 3 
± 3 d 5 7 
± 3 d 7 1 
± 3 d 8 5 
± 3 d 
Nas al or nas op har yn geal 
s wa b XAt scree ni n g, o nl y  if 
S A R S -C o V -2 p oi nt -of -
care test will n ot be 
a vaila ble f or 
Da y - 1. P ost -baseli ne, 
a d diti o nal nasal or 
nas o p har y n geal s wa bs 
m a y  be c o n d ucte d f or 
researc h p ur p oses. See 
Secti o n 8. 3. 7 .
A d missi o n t o st u d y 
site /c hec k i n (a d missi o n 
da y  m a y  var y  de pe n di n g 
o n I P a vaila bilit y) XIf scree ni n g is 
c o n d ucte d wit hi n 3 da ys 
of c hec k -i n, partici pa nts 
m a y  st a y at t he st u d y 
site bet wee n scree ni n g 
a n d c hec k i n . See 
Secti o n 4. 1 f or details. 
S A R S -C o V -2 p oi nt -of -
care test XO n Da y - 1, i f 
nasal/ nas o p har y n geal 
s wa b was n ot perf or me d 
at scree ni n g. Ad diti o nal 
p oi nt -of -care test sma y 
be c o n d ucte d at t he 
i n vesti gat or’s 
discreti o n . See Secti o n 
8. 3. 7 .
Disc har ge fr o m st u d y 
site X
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
11Procedure / 
AssessmentsScreening Dosing Postdose Follow -up Visits
Comment Visit NumberV1 V2 V3 V4 V5 V6 V7 V8 V9V10/
ED
Week(s) 0 1 2 3 4 6 8 10 12
Study Day-14
to –2-1 1 2 3 4 8
±1d15
±2d22
±2d29
±3d43
±3d57
±3d71
±3d85
±3d
Physical examination
(PE)/Medical assessment
(MA)X X Predose X As needed XFull PE/MA at 
screening and Visit 
10/ED .Symptom -
directed PE/MAat all 
other indicated time 
points andas deemed 
necessary by the 
investigator.
Vital signs: blood 
pressure, pulse rateaX XPredose, every 
15 min during 
infusion ; every 
30 min until 2h 
after endof 
infusion ;then 
every 60 min 
until 6h after 
endof infusion .24h 
(±2 h)48 h
(±2h)X X X X X X X X XVital signs should be 
taken following an at 
least 5-min rest in a 
supine position. Vital 
signs may be taken any 
time prior to dosing.
Body temperature X XPredose, 6 h 
(±15 min)24 h 
(±2h)May be performed at 
additional time points at 
the discretion of the 
investigator.
Single 12 -lead ECGaXPredose , 
1 h (±10 min) , 
6 h (±15 min)24 h
(±2 h)48 h
(±2h)X X X XAll ECG s are local. 
Predose ECG can be 
taken any time prior to 
dosing on same day.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
12Procedure / 
AssessmentsScreening Dosing Postdose Follow -up Visits
Comment Visit NumberV1 V2 V3 V4 V5 V6 V7 V8 V9V10/
ED
Week(s) 0 1 2 3 4 6 8 10 12
Study Day-14
to –2-1 1 2 3 4 8
±1d15
±2d22
±2d29
±3d43
±3d57
±3d71
±3d85
±3d
Concomitant medications 
and AE reviewX X Predose X X X X X X X X X X XAE only after 
participant has signed 
the study informed 
consent form.
HIV, hepatitis B/C 
serologyX
Pregnancy test(women 
only)b X XSerum pregnancy test at 
screening . Day -1 urine 
test refers to test at 
check -in; this is not 
needed if check -in 
occurs on same day as  
screening . Postdose 
urine test(s) can be 
performed at the 
judgment of the 
investigator, if 
pregnancy is suspected.
Clinical lab oratory testsaX Predose X X X X X X X XFasting is not required 
for these tests.
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
1 3 Pr oce d ure / 
Assess me nts Scree ni n g D osi n g P ost d ose F oll o w -u p Visits 
C o m me nt Visit N u m ber V 1 V 2 V 3  V 4 V 5  V 6  V 7  V 8  V 9 V 1 0/ 
E D 
Wee k(s) 0 1 2 3 4 6 8 1 0 1 2 
St u d y D a y - 1 4 
t o –2- 1 1 2 3 4 8 
± 1 d 1 5 
± 2 d 2 2 
± 2 d 2 9 
± 3 d 4 3 
± 3 d 5 7 
± 3 d 7 1 
± 3 d 8 5 
± 3 d 
Breat h or uri ne e t ha n ol 
scree n XEt ha n ol test is o n t he 
da y  of c hec k -i n. I f 
scree ni n g visit is t he 
sa me as da y of c hec k -
i n, n o f urt her et ha n ol 
test is re q uire d .Et ha n ol 
scree n ma y be re peate d 
at ot her ti me p oi nts at 
t he discreti o n of t he 
i n vesti gat or. 
Uri ne dr u g scree n X  X Da y -1 uri ne test refers 
t o test at c hec k -i n; t his 
is n ot nee de d if c hec k -
i n occ urs o n sa me da y 
as scree ni n g. Dr u g 
scree n ma y be re peate d 
at ot her ti me p oi nts at 
t he discreti o n of t he 
i n vesti gat or. 
IV L Y 3 8 3 2 4 7 9 or 
place b o d osi n g XPartici pa nts will be 
ra n d o mize d t o recei ve 
eit her L Y 3 8 3 2 4 7 9 or 
place b o. D osi n g ma y be 
dela ye d d ue t o I P bei n g 
u na vaila ble ; see Secti o n 
4. 1 .
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
1 4 Pr oce d ure / 
Assess me nts Scree ni n g D osi n g P ost d ose F oll o w -u p Visits 
C o m me nt Visit N u m ber V 1 V 2 V 3  V 4 V 5  V 6  V 7  V 8  V 9 V 1 0/ 
E D 
Wee k(s) 0 1 2 3 4 6 8 1 0 1 2 
St u d y D a y - 1 4 
t o –2- 1 1 2 3 4 8 
± 1 d 1 5 
± 2 d 2 2 
± 2 d 2 9 
± 3 d 4 3 
± 3 d 5 7 
± 3 d 7 1 
± 3 d 8 5 
± 3 d 
L Y 3 8 3 2 4 7 9 P K 
sa m pli n g aPre d ose ,
e n d of i nf usi o n 
( ± 1 0 mi ns) ,
6 h o urs ( ± 3 0 
mi ns) after st art 
of i nf usi o n .2 4 h 
( ± 2 h) 4 8 
( ± 2 h) X  X X  X  X XPre d ose c ollecti o n 
s h o ul d be ta ke n wit hi n 
1 5 mi n bef ore d osi n g. 
T he e xact ti me of dra w 
m ust be rec or de d .
I m m u n o ge nicit y sa m ple aPre d ose X X X X
Ser u m sa m ple f or 
e x pl orat or y bi o mar kers aX X X X X X
P har mac o ge netics 
sa m ple aPre d ose F or st ora ge o nl y. 
A b bre viati o ns: A E = a d vers e e ve nt; C O VI D -1 9 = c or o na vir us disease 2 0 1 9; E C G = electr ocar di o gra m; E D = earl y disc o nti n uati o n; HI V = h u ma n 
i m m u n o deficie nc y vir us; I/ E = i ncl usi o n/e xcl usi o n criteria; I V = i ntra ve n o us; P K = p har mac o ki netics; S A R S -C o V -2 = se vere ac ute res pirat or y s y n dr o me 
c or o na vir us 2; V = Visit 
aW he n c o n d ucte d o n t he sa me da y, t he or der of pr oce d ures s h o ul d be vital si g ns ,E C G ,a n d t he n bl o o d sa m pli n g. 
bF or w o me n w h o are c o nsi dere d t o be p ost me n o pa usal, f ollicle -sti m ulati n g h or m o ne s h o ul d be dra w n t o c o nfir m p ost me n o pa usal stat us if necessar y, acc or di n g t o A p pe n di x 4 
( Secti o n 1 0. 4 ). 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
152. Introduction
Given t he current epidemio logic emergency caused by  the coronavi rus di sease 2019 (COVID-19)
pandemic , 
Eli Lilly and Co mpany (Lilly) is seeking opportunit ies to ident ify potential 
prophylact ic and treatment options to help in the prevent ion and control of this public healt h 
issue. Recent ly, Lilly entered into a co -development agreement with TopAlliance Biosciences, 
Inc. to develop LY38 32479 (al so known as JS016-CB6, JS016, or CB6) . LY3832479 is a 
recombinant, fully human neutralizing monoclo nal immunoglobulin ( Ig) G1 kappa antibody  with 
abrogated Fc effector funct ion.
2.1. Study Rationale
Lilly is developing LY3832479 for the treatment and prevention of COVID -19. Study J2Z-MC-
PGAA (PGAA) will invest igate the safet y, tolerabilit y, andpharm acokinet ics (PK) of 
LY3832479 when administered as a single intravenous (IV) dose to healthy participants.
2.2. Background
The viral patho gen causing the COVID -19 pandemic is the severe acute respiratory  syndro me 
coronavirus 2 (SARS -CoV -2). Viral entry  into host cells invo lves its structural Spike 
glycoprotein. The Spike glycoprotein attaches itself via its receptor -binding domain (RBD) to t he 
human angiotensin- converting enzyme 2 (ACE2), enabling sufficient proximit y for the virus to 
fuse wit h the target cell membrane .ACE2 is expressed in the membrane of various cell t ypes in a 
variet y of tissues, primarily  inthelung, small intestine, kidney ,and vascular endothelium 
(Hamming et al. 2004; Human Protein AtlasProject website [WWW] ).
LY3832479 specifically  binds the Spike glycoprotein RBD wi th high affinit y, prevent ing its 
interact ion with the ACE2 human receptor. This in turn blocks viral cell fusio n, prevent ing 
SARS -CoV -2 invasio n of human cells, inhibit ing viral replicat ion. As the binding epitope of 
LY3832479 to RBD covers the most conserved RBD/ACE2 interaction site based on an analysis 
of the LY3832479- RBD com plex x -ray structure, LY3832479 is expected to neutralize all 
currently described viral strains.
The amino acid sequence of recombinant ant ibody  LY3832479 was derived fro m human 
memory  B cells of a convalescent patient with COVID -19. Therefore, format ion of antidrug 
antibodies (ADAs) and rel ated si de effects is unlikely. To further reduce potential toxicit y to 
human cells, point mutations ( L234A, L235A; LALA mutation ) were introduced into the Fc 
domain o f the nat ive human IgG1 ant ibody  to eliminate Fc effec tor function, to reduce the risk of 
antibody -dependent enhancement (ADE) .
2.3. Benefit/Risk Assessment
Concurrent with Study  PGAA, LY3832479 is being developed in China inanongoing Phase 1 
clinical study in healt hy participants, Study  JS016 -001-I. The first cohort of Study  JS016 -001-I 
was dosed on 07 June 2020, with 3 participants receiv inga single infusio n of 2.5 mg/kg of 
LY3832479 and 1participant receiv ingplacebo. As of 23 June 2020 , LY3832479 waswell 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
1 6 t ol erate d . T he o nl y a d verse e ve nt re p or te d was a mil d a n d tra nsie nt i ncrease i n ser u m creat i ni ne 
i n 1 partici pa nt. 
T he n o ncli nical safet y p ac ka ge i ncl u des t h e f o ll o wi n g st u di es liste d. 
a si n gle -d ose t o xi c o l o g y /t o xic o ki netic ( T K) st u d y  t hat al s o e val uates t he T K of 
L Y 3 8 3 2 4 7 9 i n c y n o m o l g us m o n ke ys. 
A g o o d la b orat or y  practi ce ( G L P )- c o m plia nt 2 1 -da y re peat -d ose (2 5, 7 5 , 2 0 5m g/ k g 
e ver y 3 da ys )st u d y  i n c y n o m o l g us m o n ke ys wit h a 6 -wee k rec o ver y  p eri o d. T hi s st u d y  
eval uate dT K a n d safet y p har mac o l o g y .
G L P -c o m pl ia nt  tiss ue cr oss -reacti vit y ( T C R) st u dies i n h u ma n a n d c y n o m o l g us tiss ues .
A n i nt eri m re p ort i ncl u di n g i n -life data fr o m t he d osi n g p hase f or t he re peat -d ose st u d y  was 
a vaila ble at t he ti me of t h e i nit ial I B. A n a d dit i o nal i nteri m re p ort i ncl u di n g hist o pat h ol o g y , 
res pi r at or y  f u nct i o n a n d T K data is e x pecte d t o be a vaila ble earl y d uri n g t he c o n d uct of t his 
P hase 1 st u d y . A fi nal re p ort f or t he re peat -d ose st u d y is e x pecte d t o be s u b mitte d after t he 
c o m plet i o n of t he rec o ver y  p hase. T he I B will be u p date d w he n a d dit i o n al  i nf or mat i o n is 
re p orte d. 
The precli nical st u di es bei n g carri e d o ut s u p p ort t he cli nical de vel o p me nt of L Y 3 8 3 2 4 7 9 a gai nst 
a f orei g n tar get . 
Alt h o u g h t here is a n o n g oi n g first -i n -h u ma n cli nical st u d y  testi n g L Y 3 8 3 2 4 7 9 i n healt h y 
parti ci pa nts i n C hi na ( St u d y  J S 0 1 6 - 0 0 1 -I), o nl y  li mi te d data fr o m  t hat st u d y  are a vaila ble at t his 
ti me. T heref ore, S t u d y  P G A A has bee n desi g ne d t o be c o n d ucte d i n acc or da nce wit h pri nci pl es 
o utli ne d i n t he G ui deli ne o n Strate gies t o I de ntif y a n d Mit i gate Ri s ks f or Fir st -i n - H u ma n Cli nical 
Tri als wi t h  I n vest i gat i o nal Me dici nal Pr o d ucts ( E M A 2 0 1 7). A n y i de nt ifie d ris ks are c o nsi dere d 
t o be m o ni t ora ble a n d ma na gea ble at t he pla n ne d d ose ra n ge of  7 0 0 t o 7 0 0 0 m g L Y 3 8 3 2 4 7 9 i n 
healt h y parti ci pa nts .
T here i s n o a ntici pate d t hera pe uti c be nefi t f or t he parti ci pa nts .
T he oretical ris ks relate d t o i nf usi o n of L Y 3 8 3 2 4 7 9 are: 
Se vere a c ute i nf usi o n react i o n. T his ris k is decrease d d ue t o 
oL Y 3 8 3 2 4 7 9 bei n g di recte d a gai nst a f o rei g n tar get 
ot h e h u ma n ori gi n o f L Y 3 8 3 2 4 7 9 , a n d 
ot h e re d uce d Fc effect or f u nct i o n
Ot her h y perse nsi ti vi t y  react i o ns as f or a n y  ot her pr otei n pr o d uct 
A nt i b o d y -de pe n de nt e n ha nce me nt of  vi r al  re plicat i o n i n case a n y  of  t hese healt h y 
v o l u nteers c o ntrac ta S A R S -C o V -2 i nfect i o nw hile t he y  still ha ve si g nifica nt L Y 3 8 3 2 4 7 9 
e x p os ure after a si n gle I V i nf usi o n. T his p he n o me n o n has bee n o bser ve d wit h s o me ot her 
vir uses i ncl u di n g t he de n g ue vir us, b ut is o nl y a t he oretical ris k wit h o ut cli nical e vi de nce 
i n t he case of res pi r at or y  c or o na vi r uses ( Gra ha m  2 0 2 0) . I n a d dit i o n, L Y 3 8 3 2 4 7 9 was 
s peci fi call y e n gi neere d t o a v oi d t his ri s k as e x plai ne d i n Secti o n 2. 2 . 
U n k n o w n ris ks relate d t o o n -tar get a n d off -tar get t o xi ci t y . T hese ris ks ar e l o w d ue t o t h e
ofact t hat L Y 3 8 3 2 4 7 9 tar gets a f orei g n pr otei n, 
oh u ma n ori gi n o f L Y 3 8 3 2 4 7 9 (t he L A L A m utati o n sd o n ot i n v o l ve t he R B D of  
L Y 3 8 3 2 4 7 9 ), a n d 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
17oabsence of binding in the TCR studi es perform ed in humans and m onkeys . 
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected adverse events (AEs) ofLY3832479 may be found in the IB. 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
183. Objectives and Endpoints
Object ives Endpoints
Primary
To investigate the safet y and 
tolerabilit y of a single dose of 
LY3832479 in healt hy part icipantsSerious and nonserious adverse 
events, l aboratory  measures of safet y, 
ECG, and vital signs
Secondary
To characterize the pharmacokinetics 
of LY3832479 following a single IV
administration of LY3832479 to 
healt hy participantsAUC, Cm ax
Abbreviations: AUC = area under the concentration versus time curve; Cmax = maximum observed drug 
concentration; ECG = el ectrocardiogram; IV = intravenous.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
194. Study Design
4.1. Overall Design
Study  PGAA is a Phase 1, randomized, placebo -controlled study ofLY3832479 administered to 
healt hy participants.
Screening
Each participant will provide informed consent for study  parti cipat ion and will undergo a 
screening examinat ion within 14days prior to enrollment .
Parti cipants may  be offered the possibilit y of staying at the study  site between screening and 
dosing. In addit ion, the day of dosing may  be delayed by  up to 3 day sin the event invest igational 
product is unavailable . 
The day  of dosing will always be designated as Day  1,the day  before dosing will always be 
designated as Day  -1,and subsequent activit ies carri ed out per the timings in the SoA.
Parti cipants will be discharged on Day  4, and subsequent ly monitored on an outpatient basis 
until the last fo llow-up visi t.  
In the event of such a delay , the following assessments conducted on Day  -1 shoul d be repeated 
on subsequent days unt il dosing:
COVID -19 clinical screening, 
review/confirm eligibilit y criteria, 
vital signs, 
body  temperature, 
concomitant medicat ions, and 
adverse events.
4.1.1. Single -Ascending Dose De sign
The study  will com prise up to 3 cohorts, each with an intended number of participants as 
follows:
Cohorts 1 and 2
At least 9 participants
7 randomized to LY3832479 and
2 randomized to placebo.
Cohort 3
At least 8 participants
6 randomized to LY3832479 and
2 randomized to placebo.
A maximum of 30 participants will be enro lled to study intervent ion such that approximately 
8 parti cipants have sufficient evaluable data in each cohort.
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
2 0 After at l east 7 parti ci pa nts ha ve c o m p lete d Da y  4 i n a gi ve n c o h ort (s ee Secti o n 4. 2 f o r 
r ati o nale) , all  s af et y data u p t o t his c ut off date will be re vie we d t o deter mi ne w het her t he ne xt 
c o h ort ca n be d ose d, as well as t h e d ose t o be use d, aft er a gree m e nt bet wee n t he Lill y’s me dical 
m o nit or a n d t he i n vesti gat or. Safet y a n d t ol era bilit y data will be t he pri mar y criteria g ui di n g d ose 
escalat i o n. 
T he i n vest i gat or a n d t he Lill y s p o ns or tea m are res p o nsi ble f or deter mi ni n g a n y d ose decisi o ns. 
T he i n vest i gat or(s) will re mai n bli n de d a n d t he Lill y s p o ns or tea m will be u n bli n de d d uri n g t hese 
re vie ws. All a vaila ble data fr o m pre vi o us c o h orts will be re vie we d. 
4. 2. Scie ntific R ati o n ale f or St u d y Desi g n 
T his st u d y  i s desi g ne d t o e x pl ore a ra n ge of d oses t hat will i nf or m t he cli nical dr u g de vel o p me nt 
pl a n f or L Y 3 8 3 2 4 7 9. 
T he se q ue nt ial c o h ort, si n gle -d ose escalat i o n desi g n wit h safet y re vie ws bef ore eac h c o h ort will 
mi ni mize safet y ri s ks t o parti ci pa nts d u ri n g d ose e x pl orati o n. 
Se nt i nel d osi n g is n ot i ncl u de d i n t his desi g n as L Y 3 8 3 2 4 7 9 is n ot c o nsi dere d a hi g h u ncertai nt y 
c o m p o u n d b ase d o n it s ori gi n , str uct ure, me c ha nis m o f act i o n/ p har m a c ol o g y  tar get (i t is di recte d 
a gai nst a f orei g n tar get) ,a n d n o ncli n ical data : 
No t o xicit y was o bser ve d i n t he si n gle -d ose m o n ke y T K st u d y (st u d y  re p ort pe n di n g) .
L Y 3 8 3 2 4 7 9 is a m o n ocl o nal  a nt i b o d y (m A b )di recte d a gai nst a f orei g n tar get a n d was 
is o lat e d f r o m  a c o n valesce nt patie nt wi t h  C O VI D - 1 9 ; t heref ore, it has a l o w r is k f o r o n -
tar get or off -tar get t o xici t y .
T he ri s k of i nf usi o n- r el ate d reacti o n is c o nsi dere d l o w d ue t o t he tar get, t he re d uce d 
effect or f u nct i o n ( Fc a n d C o m p le me nt bi n di n g), a n d t he h u ma n ori gi n of t his a nti b o d y .
T he e n gi neere d L A L A m utati o n sare e x pecte d t o re d uce Fc effect or f u nct i o n i n 
L Y 3 8 3 2 4 7 9 a n d s h o ul d re d uce t he ris k of A D E. 
T he 4 -d a y  safet y re vie w after d osi n g is s ufficie nt t o detect a n ac ute a d verse i m m u ne res p o nse t o 
treat m e nt wi t h  L Y 3 8 3 2 4 7 9 t h at w o ul d pre cl u de d ose escalat i o n. 
4. 3. J u stific ati o n f or D ose 
T he d ose le vels f o r t hi s st u d y  are desi g ne d t o e x pl ore a wi de e x p os ure ra n ge t hat p ote ntiall y 
e nc o m pass es t h e t hera pe uti c d ose ,a n d will pr o vi de t he safet y a n d t ol era bilit y u n der pi n ni n gs f or 
t h e cli nical dr u g de vel o p me n t pl a n f or L Y 3 8 3 2 4 7 9. D ue t o t he u ncertai nt y of  i n vit r o t o i n vi v o 
tra nsl at i o n a n d u ncertai nt y i n tra nslat i o n of data fr o m a r hes us maca q ue S A R S -C o V -2 i nfecti o n 
m o d el  t o h u m a ns, 3 m et h o ds were ut ilize d t o pre dict a n efficaci o us h u ma n d ose ra n ge of 2 0 0 0 t o 
7 0 0 0 m g. 
T he first met h o d i n v ol ve d i de nt if yi n g a h u ma n d ose t hat w o ul d , i n t he m aj ori t y  of  p ati e nts (m o re 
t h a n 9 0 %) ,ac hie ve tr o u g h l u n g c o nce ntrati o ns ( Da y 2 8 after d osi n g) greater t ha n t h e 
c o nce ntrati o n t h at was f o u n d t o ne utralize 9 0 % of t he vir us (I C 9 0 )i n vitr o . T his a p pr oac h use d 
t h e h u ma n P K as pr ojecte d fr o m t he m o n ke y T K st u d y  a n d i nc or p orate d dr u g distri b ut i o n i nt o 
l u n g tiss ue ( S ha h a n d Betts 2 0 1 3 ;Ma g yar ics et al . 2 0 1 9 ). T his a p pr oac h i de nt ifie d a d ose of 
2 0 0 0 m g. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
2 1 T he sec o n d me t h o d i n v o l ve d de vel o pi n g a se mi -mec ha nist ic S A R S -C o V -2 vi r al  d y na mic m o d el  
(Ki m et al. 2 0 2 0) as a da pte d fr o m a t y pical vi r al  d y na mic m o d el  ( Ca n gel o si et al . 2 0 1 8 ). T hi s 
met h o d ai me d t o i de ntif y a d ose t hat w o ul d res ult i n t he m ost ra pi d cleara nce of vir us fr o m a 
patie nt a n d i de nt ifie d a d ose of 3 0 0 0 m g. 
T he t hi r d m et h o d was t o fi n d a d ose t hat w o ul d ac hie ve h u ma n ser u m  c o nce ntrati o ns t h r o u g h o ut 
a 2 8 -d a y  d osi n g i nter val e q ui vale nt t o ser u m c o nce ntrati o ns i n a s uccessf ul r h es us maca q ue 
S A R S -C o V -2 c halle n ge st u d y . T his m et h o d i de ntifie d t hat a d ose of 7 0 0 0 m g ma y  b e r e q ui re d. 
T he pr oj ecte d h u ma n half -life of L Y 3 8 3 2 4 7 9, base d o n all o metric scali n g fr o m m o n ke y data, is 
e x pecte d t o be i n t he 2 -t o 4 -wee k ra n ge .
S af et y mar gi ns f or t he pr o p ose d starti n g a n d ma xi m u m d ose i n t his st u d y are s h o w n i n 
Ta ble 4. 1 .
T he pr o p ose d starti n g h u ma n d ose of  7 0 0 m g has a 1 0 -f o ld m ar gi n of  safet y f o r e val uati o n of 
safet y,  t ol era bili t y , a n d P K base d o n e x pecte d e x p os ure ( A U C) r el at i ve t o t he ma xi m u m teste d 
d ose i n a si n gle -d ose m o n ke y t o xi ci t y /T K st u d y . T he s u bse q ue nt d oses of 2 8 0 0 a n d 7 0 0 0 m g i n 
t h e si n gle -asce n di n g d ose c o h orts are pla n ne d t o be a d mi nistere d f o ll o wi n g i nteri m safet y data 
fr o m t h e pre vi o us c o h orts as descri be d i n Sect i o n 6. 6 . T he hi g hest pr o p ose d d ose, 7 0 0 0 m g, 
w o ul d ha ve a 1 x mar gi n of safet y. T his mar gi n of safet yis c o nsi dere d acce pta ble f or t he 
f o ll o wi n g reas o ns: 
L Y 3 8 3 2 4 7 9 is a m A b directe d a gai nst a f orei g n tar get a n d was is o lat e d fr o m a 
c o n valesce nt pati e nt wit hC O VI D - 1 9. T heref ore, t he test article d oes n ot bi n d t o 
a nt i ge ns/tar gets e x presse d i n h u ma n t iss ues as c o nfi r m e d b y  a G L P -c o m plai nt T C R st u d y  
i n h u ma n t is s ues , re prese nti n g a l o w ri s k f or p ote ntial o n -tar get or off -tar get t o xi ci t y .
T he 1 xe x p os ure -base d mar gi n f or 7 0 0 0 m g is base d o n t he ma xi m u m d ose teste d i n 
m o n ke ys i n t he si n gle -d ose t o xi c o l o g y /T K st u d y .Base d o n cli nical o bser vat i o ns a n d 
gr oss e xa mi nat i o n at necr o ps y , n o t o xi ci t y  was o bser ve d i n t he a ni mals a d mi nistere d 
1 8 6 m g/ k g of L Y 3 8 3 2 4 7 9 (fi nal re p ort pe n d i n g) .
T h eri s k of i nf usi o n- r el ate d reacti o n is c o nsi dere d l o w d ue t o t he tar get , t he re d uce d 
effect or f u nct i o n ( Fc a n d C o m p le me nt bi n di n g ), a n d t he h u ma n ori gi n of t his a nti b o d y .
T he e n gi neere d L A L A m utati o n s are e x pecte d t o re d uce Fc effect or f u nct i o n i n 
L Y 3 8 3 2 4 7 9 a n d s h o ul d re d uce t he ris k of A D E (see Secti on 2. 2 ). 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
22Table 4.1. Margin of Safety for Intravenous Administration of LY3832479 Based on 
Administered Dose and Predicted Exposure
Dose
(mg/kg)Dose
Multiple aAUC0 -∞
(mg*h/mL)aAUC 
Exposure 
Multiple aCmax 
(mg/mL)Cmax 
Exposure 
Multiplea
Starting h uman dose b 10 18.6 75 ~10 0.253 ~19
Highest human dose b 100 1.86 753 ~ 1.0 2.5 1 ~1.9
Cyno molgus monkey
maximum tested dosec186 750 4.75
Abbreviations: AUC = area under the concentration versus time curve; AUC0 -∞= AUC from time zero to infinity; 
Cmax = maximum drug concentration; NOAEL = no -observed -adverse -effect level.
aDose multiple is the dose in animals/dose in humans based on milligrams per kilogr am.Exposure multiple is the 
calculated AUC and Cmax in animals and predicted AUC and Cmax in humans. 
bAssume 70 -kg bodyweight .
cMaximum tested dose in the single -dose monkey toxicology/toxicokinetic study.
4.4. End of Study Definition
A participant is consi dered to have com pleted the study  if he/she has co mpleted all requi red
phases of the study  including the last scheduled procedure shown in the Schedule of Act ivities
(SoA) .
The end o f the study  is defined as the date of last scheduled procedure shown in the SoA for the 
last parti cipant.
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
2 3 5. St u d y P o p ul ati o n 
Pr os pecti ve a p pr o val o f pr ot oc ol  de viati o ns t o recr ui t m e nt a n d e nr o ll me nt criteria, als o k n o w n as 
pr ot oc ol  wai vers or e xe m pt i o ns, is n ot per mitte d. 
5. 1. I ncl usi o n Criteri a 
Par ti ci pa nts are eli gi ble t o be i ncl u de d i n t he st u d y o nl y if all o f t h e f ol l o wi n g criteria a p pl y: 
A ge 
1. are a ge d 18t o 6 0 years at t he ti me of si g ni n g t he i nf or me d c o nse nt. 
T y pe of P artici p a nt a n d Dise ase C h ar acteristics 
2. are o vertl y healt h y as de ter mi ne d b y me dical e val uati o n i ncl u di n g me dical hist or y a n d 
p h ysical e xa mi nat i o n
3. ha ve safet y la b orat or y  test res ul ts wi t hi n t h e r ef ere nce ra n ge f o r t he p o p ul at i o n at t he 
st u d y si te, or res ul ts wi t h  acce pta ble de viat i o ns t hat are j u d ge d t o be n ot cli nicall y 
si g nifica n t b y  t he i n vest i gat or 
4. ha ve ve n o us access s ufficie nt t o all o w f or bl o o d sa m pli n g a n d I V i nf usi o nas descri be d i n 
t hi spr ot oc ol  ( S o A, Secti o n 1. 3 )
5. are relia ble a n d willi n g t o ma ke t he msel ves a vaila ble f or t he d urati o n of t he st u d y 
6. are willi n g t o f o ll o w st u d y  pr oce d ures , i ncl u di n g ha v i n g nasal or nas o p har y n geal 
s wa bs c o llecte d as descri be d i n t his pr ot oc ol ( S o A, Secti o n 1. 3 ). 
Wei g ht 
7. ha ve a B MI wi t hi n t he ra n g e ≥ 1 8. 5 t o < 3 5 k g/ m 2.
Se x 
8. are male or fe male 
a. Male parti ci pa nts m ust a gree t o a d here t o c o ntrace pti o n restrict i o ns 
b. Fe male partici pa nts m u st be of n o n -c hil d beari n g p ote ntial 
C o ntrace pti o n re q uire me nts a n d defi nit i o n of n o n -c hil d beari n g p ote ntial are detaile d i n 
A p pe n di x 4 ( Secti o n 10. 4 ). 
I nf or me d C o nse nt 
9. are c a pa ble of gi vi n g si g ne d i nf or me d c o nse nt as descri be d i n A p pe n di x 1 ,w hic h 
i ncl u des c o m plia nce wit h t he re q uire me nts a n d restricti o ns liste d i n t he i nf or me d c o nse nt 
f o r m  (I C F) a n d i n t his pr ot oc o l
5. 2. E xcl usi o n Criteri a 
P arti ci pa nts are e xcl u de d fr o m t h e st u d y  i f a n y of t he f o ll o wi n g cri t eri a a p pl y: 
Me dic al C o n diti o ns 
1 0. ha ve c urre nt S A R S -C o V -2 i nfect i o n c o nfir me d b y nasal or nasal p har yn geal  s wa b res ul ts 
at scree ni n g 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
2411.have had prior SARS -CoV -2 infect ion, confirmed by  either previ ous nucleic acid-based 
test, or previous serology
12.have suspected current SARS -CoV -2 infect ion, in the opi nion of the invest igator ,based 
oneither or both of the fo llowing:
a. a recent exposure to SARS -CoV -2, defined as:
living in the same househo ld as a person with SARS- CoV -2
having had direct physical contact with a person wit h SARS -CoV -2(e.g. 
shaking hands);
having unprotected direct con tact wi th infect ious secreti ons of  a person wi th 
SARS -CoV -2(e.g. being coughed on, touching used paper tissues with a bare 
hand) ;
having had face -to-face contact with a person with SARS -CoV -2, within 2 m 
and for more than 15 minutes
b.signs or symptom s that, in the opinio n of the investigator, are suggestive of 
infect ion (e.g., fever, dry  cough, shortness of breath, hypoxia, etc.)
13.have a history  or presence of cardiovascular (including hypertensio n), respi ratory , 
hepat ic, renal, gastrointest inal, endocrine, hematologi cal, or neurol ogical disorders that, 
in the opinio n of the invest igator, are capable of 
a.significant ly altering the abs orpti on, m etabo lism, or eliminat ion of drugs
b.consti tuting a ri sk wh ile taking the invest igational product, or
c.interfering wi th the interpretati on of  data
14.have clinically  significant abnorm al electrocardi ogram  (ECG )results constituting a risk 
while taking the invest igational product, as determined by  the invest igator
15.have an abnormal blood pressure (BP) as determined by the invest igator. In case BP 
appears to be abnormally high during the screening period, it is possible to repeat the 
measure(s) 1 time in a quiet room  to avoi d an exclusion due to the white coat effect
16. have significant allergies to humanized mAbs
17.have any of the fo llowing that are clinically significant :
a.multiple or severe drug allergies, or 
b.intolerance to topi cal corti costeroi ds, or 
c.severe posttreatment hypersensit ivity react ions (including, but not limited to, 
erythema m ultiforme maj or, linear immunogl obulin A derm atosis, toxic 
epidermal  necrolysis, or exfoliat ive dermat itis)
18.have known allergies to LY3832479 , related compounds, or any  com ponents of the 
formulation
19.have had lympho ma, leukemia, or any  malignancy  within the past 5 years, except for 
basal cell or squamous epithelial carcino mas of the skin that have been resected with no 
evidence of metastatic disease for 3 y ears 
20.have had brea st cancer within the past 10 y ears
21.show evidence of human immunodeficiency  virus (HIV) infecti on and/or posit ive human 
HIV antibodie s
22.show evidence of current hepat itis C (that is, test posit ive for anti-hepati tis Cantibody  
with confirmed presence of hepa titis C vi rus [HCV] RNA)
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
25Note: Patients with a previous diagnosis of hepat itis C who received antiviral therapy and 
achieved a sustained viro logical response may be eligible for inclusio n in the study , 
provi ded that they  have no detectable HCV RNA on the screening HCV polymerase 
chain react ion test for this protocol. A sustained virol ogical  response is defined as an 
undetectable HCV RNA level 24 weeks after complet ion of a full, docum ented course of 
an approved ant iviral therapy for HCV.
Patients who have spontaneously cleared HCV infection, defined as (1) a positive HCV
antibody  test and (2) a negative HCV RNA test, with no history  of HCV antibody  (anti -
HCV) treatm ent, may  be eligible for inclusio n in the study ,provi ded that they  have no
detectable HCV R NA at screening for this study .
23.show evidence of current hepat itis B:
a.test posit ive for hepat itis B surface ant igen, and/or
b.test posit ive for hepat itis B core antibody  and negative for hepatit is B surface 
antibody
24.have a significant history o f or current psychiatric di sorders
Prior/ Concomitant Therapy
25.have received treatment with bio logic agents (such as mAbs, including marketed drugs) 
within 3 m onths or 5 half -lives (whichever is longer) prior to dosing
26.have previously completed or withdrawn fro m this study and have previously received 
theinvest igational product
27.intend to use over -the-counter m edicat ion in the 7 days prior to dose administration or 
prescri ption medication in the 14 days prior to dose administration, with the except ion of 
horm one repl acement therapy , thyroid replacement medicat ions, vitamin and mineral 
supplements, a nd occasional use of acetaminophen
Prior/Concurrent Clinical Study Experience
28.are currently enrolled in a clinical study  involving an invest igational product or any  other 
type of medical research judged not to be scient ifically or medically  com patible wit h this 
study
29.have participated in a clinical study  involving an investigational product , with last dose
within the past 30  days or 5 half -lives (whichever is longer ) prior to dosing
Other Exclusions
30. a re pregnant or breast feeding
31. have donated blood of more than 500 mL within the previous 3 months of study  
screening, or intend to donate blood during the course of the study
32.have an average weekly  alcohol  intake that exceeds 21units per week (males) or 14units 
per week (females), or are unwilling to stop alcohol consumpt ionfrom 48 hours prior to 
admissio n to and while resident at the clinical research unit ( CRU )(1 unit = 12 oz or 360 
mL o f beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL o fdistilled spirits)
33.currently smoke in excess of 10 cigarettes per day  or are unwilling to abide by  CRU 
smoking restricti ons
34.regul arly use known drugs of abuse and/or show posit ive findings on drug screening 
unless they  were prescribed by a physician (e.g. benzodiazepines).
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
2 6 3 5. are Lill y  e m pl o y ees or are e m pl o y ees of a t hi r d -p art y  or ga ni zat i o n i n v o l ve d wi t h  t he 
st u d y  t hat re q ui res e xcl usi o n of  i ts e m pl o y ees are st u d y  s it e pers o n nel direct l y affiliate d 
wi t h  t his st u d y  or t hei r i m me diate fa milies. I m me diate fa mil y is defi ne d as a s p o use, 
bi o l o gical  or le gal g uar dia n, c hil d, or si bli n g. 
3 6. i n t he o pi ni o n of t he i n vest i gat or or s p o ns or, are u ns uita ble f or i ncl usi o n i n t h e st u d y .
5. 3. Lifest yle C o nsi der ati o ns 
Re pr o d ucti ve a n d c o ntrace pti ve g ui da nce is pr o vi de d i n Secti o n 1 0. 4 , A p pe n di x 4. 
5. 3. 1.  Me als a n d Diet ar y Restricti o ns 
P arti ci p a nts will be re q ui re d t o fast o ver ni g ht or f or at least 4h o urs bef ore bei n g gi ve n a d ose of 
L Y 3 8 3 2 4 7 9 (see S o A , Secti o n 1. 3 ). Per oral i nta ke s h o ul d be li mite d t o clear li q ui ds f or 4 h o urs 
pri or t o d osi n g .Sta n dar d meals will be a d mi nistere d w hile part ic i pa nts are resi de nt at t he st u d y 
si t e .
5. 3. 2. C affei ne, Alc o h ol, a n d T o b acc o 
P arti ci pa nt s m u st a bi de b y  t he C R U restri ct i o n p olic y  re gar di n g c o ns u m pt i o n of alc o h o l a n d 
t o bacc o. 
5. 3. 3. Acti vit y 
P arti ci p a nts s h o ul d n ot e n ga ge i n stre n u o us p h ysical e xercise or acti vit ies fr o m 4 8 h o urs pri or t o 
d osi n g u nt il disc har ge fr o m t he st u d y or c o m plet i o n of all st u d y  pr oce d ures. W he n certai n st u d y 
pr oce d ures are i n pr o gress at t he site, partici pa nts ma y be re q uire d t o re mai n s u pi ne or sitti n g .
5. 4. Scree n F ail ures 
Scree n fail ures are defi ne d as part ic i pa nt s w h o c o nse nt t o partici pate i n t he cli nical st u d y b ut are 
n ot s u bse q ue ntl y e nr olle d i n t he st u d y . 
I n di vi d uals w h o f ulfill eli gi bilit y cri teria b ut are n ot ra n d o mize d wi t h i n t he 1 4 -d a y  scree ni n g 
wi n d o w ma y still e nr oll i n t he s t u d y  pr o vi de d ra n d o mizat i o n occ urs wit hi n 2 8 da ys of t he first 
scree ni n g visit , a n d pr o vi de d t hat t he y  re peat t he nasal or nas o p har y n geal s wa b . T hese s u bjects 
d o n ot nee d t o be d oc u me nte d as scree n fail ure s. S u bjects w h o are eli gi ble b ut are n ot e nr olle d 
wi t hi n 2 8 da ys of t heir i nit ial scree ni n g visi t will nee d t o f o ll o w re -scree n pr oce d ures descri be d 
bel o w. 
F or t he p ur p oses of asses si n g eli gi bilit y,  s cree ni n g cli nical la b orat or y test sma y be re peate d if t he 
res ul t is c o nsi dere d li kel y d u e t o a tec h nical or ha n dli n g err or .
I n di vi d uals w h o d o n ot meet t he criteria f or partici pati o n i n t his st u d y  (scree n fail ure) d ue t o a 
tra nsi e nt mi n or ill ness or c o nc o mita nt me dicat i o n ma y be re -scree ne d if a n d w he n t he y  l ater 
meet eli gi bilit y cri t eri a. 
Re -scree ne d partici pa nts s h o ul d be assi g ne d a ne w scree ni n g n u m ber. W he n re -scree ni n g, all 
scree ni n g tests a n d pr oce d ures s h o ul d be re peate d ( e xce pt safet y la b orat or y  a nal yses if 
ra n d o mizat i o n is t o occ ur wit hi n 2 8 da ys o f t h e first scree ni n g tests ). I n di v i d uals m a y be re -
scree ne d o nce, a n d m u st si g n a ne w I C F. 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
276. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s)or placebo intended to be 
administered to a study  parti cipant according to the study  protocol .
6.1. Study Intervention sAdministered
Intervention Name LY3832479 Placebo
Type Biologic Not applicable
Dose Formulation Solutionfor infusi on 0.9% sodium chloride so lution
Unit Dose Strength(s) 400-mg vial Placebo
Dosage Level(s)Cohort 1: 700 mg
Cohort 2: 2800 mg
Cohort 3: 7000 mgNot applicable
Route of 
AdministrationIV infusio n IV infusio n
Use Experimental Placebo
IMP and NIMP IMP IMP
Sourcing Provi ded by Lilly Provi ded by si te 
Packaging and 
LabelingProvided in gl ass vials and 
labeled appropriatelyPersite procedure
Abbreviations: IMP = investigational medicinal product; IV = intravenous; NIMP = noninvestigational medicinal 
product . 
This following tabl edescribes the infusio n volume and rate for LY3832479. Placebo vo lume and 
rate will match the LY3832479 dose cohort.
The infusio n rate m ay be reduced as deemed necessary  if an infusio n react ion is observed. To 
ensure close monitoring, p articipants will remain in or cl ose to thei r bed for at least 6hours after 
completion of the infusio n.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
28LY3832479
Dose (mg)Volume withdraw 
from DP vial (mL)Volume of sterile 
diluent (mL)Total infusion 
volume (mL)Start infusion 
rate( duration)
700 17.5 32.5 50 100 mL/h (30 min , 
allowable range 
25 -60 min )
2800 70 None 70 100 mL/h (42 min , 
allowable range 
37 – 75 min)
7000 175 None 175 100 mL/h (105 min , 
allowable range 
100 - 150 min )
6.1.1. Infusions
6.1.1.1. Premedication for Infusions
Prem edicat ion for infusio ns is not pl anned.
6.1.1.2. Management of Infusion Reactions
All participants shoul d be m onitored cl osely, during and after infusio n as specified in the SoA, as 
there is a risk of infusion react ion and hypersensit ivity (including anaphylaxis) with any  
biological  agent.
Symptoms and Signs
Symptom s and si gns that m ay occur as part of an infusio n reaction include , but are not limited to 
fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash 
including urticaria, pruritus, myalgia, and dizziness.
Severit y of infusio n-related reactions will be assessed and reported using the Divisio n of Allergy  
and Infect ious Diseases (DAIDS) Table for Grading the Severit y of Adult and Pediatric Adverse 
Events, version 2.1 (July  2017). 
This table describes the severit y of react ions according to DAIDS.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
29Parameter Mild Moderate Severe Severe and 
Potentially 
Life-threatening
Acute 
Allergic 
ReactionLocalized urticaria 
(wheals) with no 
medical intervention 
indicatedLocalized urticaria 
with intervention 
indicated 
OR 
Mild angioedema with 
no intervention 
indicatedGeneralized urticaria 
OR
Angioedema with 
interventio n indicated 
OR
Symptoms of mild 
bronchospasmAcute anaphylaxis 
OR 
Life-threatening 
bronchospasm 
OR
Laryngeal edema
Cytokine 
Release 
SyndromeaMild signs and 
symptoms 
AND
Therapy , that is, 
antibody infusion 
interruption not 
indicatedTherapy  indicated 
(that is, antibody 
infusion) interruption 
indicated
AND
Responds promptly to 
symptomatic 
treatment
OR
Prophy lactic 
medications indicated 
for ≤24 hoursProlonged severe 
signs and symptoms 
OR
Recurrence of 
symptoms following 
initial improvementLife-threatening 
consequences 
(for example, 
requiring pressor or 
ventilator support)
aA disorder characterized by nausea, headache, tachycardia, hypotension, rash, and/or shortness of breath.
Source: Division of AIDS (DAIDS) Table fo r Grading the Severity of Adult and Pediatric Adverse Events, Version 
2.1 (July 2017).
Site Needs
The site must have resuscitation equipment, emergency drugs (including but not limited to 
oxygen, IV fluid, epinephrine, acetaminophen ,and antihistamine) and appropri ately trained 
personnel available during the infusio n and for at least 6 hours after the complet ion of the 
infusio n.
Management of Infusion Reactions
Invest igators should determine the severit y of the infusio n reaction and manage infusion 
reacti ons based on thei r clinical judgment and national and internat ional guidance ( Lieberman et 
al 2015; Sim ons et al . 2015) .If an infusio n react ion occurs, then supportive care should be used 
in accordance wit h the signs and symptoms.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
306.1.1.3. Retrospective Positive Sterility Finding sfrom Prepared Study Intervention
If apositive sterili tyfindin goccurs in the terminally steril efiltered study  intervent ion,the
participants who were dosed fr om th e impacted batch shou ldbe contacted immediately and
undergo a full physical examina tionincluding, but not limited to, BP, pulse rate ,and body
temperature .
A bloodsampleshould be c ollected for culture and assayed for inflammatory markers such as 
C-reactive protein and eleva tions in white bl ood cell count s.
If the signs and symptoms indicated a participant has a possible infec tion, theywill be clinically 
managed, treated ,and f ollowed up un til resolution.AnyAEs will be recorded as appropriate.
6.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ionsreceived and any  discrepancies are reported 
and reso lved before use of the study  intervent ion.
To protect blinding, the intervent ions m ust be prepared by  unblinded si te personnel  qualified to 
prepare study  intervent ion who are not invo lved in any other st udy-related procedures.
Instructi ons for preparation will be provided by  the sponsor.
Only participants enro lled in the study  may receive study  intervent ion and only authorized site 
personnel may supply  or administer study  interventi on. All  study  intervent ionsmust be stored i n 
a secure, environmentally controlled, and mo nitored (m anual or autom ated) area in accordance 
with the l abeled storage conditions with access limited to the invest igator and authorized site 
personnel .
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance (i .e., 
recei pt, reconciliat ion, and final disposit ion records) .
Further gui dance and information for the fi nal disposi tion of  unused study  interventi ons are 
provi ded in the pharmacy manual .
6.3. Measures to Minimize Bias: Randomization and Blinding
Randomization tables for allocat ion of either LY3832479 or placebo will be prepared by  the 
statist icianor thei r designee.
Blinding will be maintained throughout the conduct of the study as described in the separate 
Blinding Plan.
Emergency  codes will be available to the invest igator. A code, which reveals the treatment group 
for a specific study  subject, m ay be opened during the study  only if the subject’s well -being 
requi res knowledge of the subject’s treatment assignment.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a subject’s treatm ent assi gnment i s warranted for m edical management of the event. The 
subject’s safet y must always be the first consideratio n in making such a determinat ion.If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
prom ptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
3 1 If a n i n vest i gat or, site pers o n nel perf or mi n g assess me nts, or partici pa nt is u n bli n de d w hile t he 
i nf usi o n is o n g oi n g, t he partici pa nt m ust be disc o nti n ue d fr o mt h e st u d y  i nt er ve nt i o n a n d t he 
i nf usi o n st o p pe d. If a n y a m o u nt of st u d y  i nt er ve nti o n was a d mi nistere d, f oll o w pr oce d ures 
acc or di n g t o t he S o A as descri be d i n Secti o n 7. 1 .
U p o n c o m plet i o n of t he st u d y , all c o des m ust be ret ur ne d t o Lill y  or i ts desi g nee .
6. 4. St u d y I nter ve nti o n C o m pli a nce 
Parti ci pa nts will recei ve st u d y  i nt er ve nt i o n di rect l y fr o m t h e i n vest i gat or or desi g nee, u n der 
me dical s u per visi o n. T he date a n d ti me of eac h d ose a d mi nistere d i n t he cli nic will be rec or de d 
i n t he s o urce d oc u me nts a n d rec or de d i n t he C R F. T he d ose of st u d y  i nt er ve nt i o n a n d st u d y  
parti ci pa nt i de nt ificat i o n will be c o nfir me d at t he ti me of d osi n g b y a me m ber of t he st u d y  si t e 
pers o n nel ot h er t ha n t he pers o n a d mi nisteri n g t he st u d y  i nt er ve nt i o n. 
6. 5. C o nc o mit a nt T her a p y 
All c o nc o mit a nt m e dicat i o ns, w het her prescri pt i o n or o ver t h ec o u nter, use d at baseli ne a n d/ o r 
d uri n g t he c o urse of t he trial, m ust be rec or de d o n t he C o nc o mita nt Me dicat i o n electr o nic case 
re p ort f or m (e C R F). Parti ci pa nts will be i nstr ucte d t o c o ns ult t he i n vest i gat or or ot her 
a p pr o priate st u d y  pers o n nel at t he st u d y si t e bef ore ta ki n g a n y ne w me di c ati o ns or s u p pl e me nts 
d uri n g t he st u d y .
I n ge neral, c o nc o mita nt me dicat i o n s h o ul d be a v o i de d. Use of c hr o nic, sta ble d oses of h or m o ne 
r e pl ace me nt t hera p y , t h y r oi d r e pl ace me nt m e dicati o ns, or vit a mi n a n d mi neral s u p ple me nts is 
all o we d. Aceta mi n o p he n ( 1 g, ma xi m u m 3g/ 2 4 h o urs) ma y be a d mi nistere d at t he discreti o n o f 
t h e i n vest i gat or f or treat me nt of hea dac he, etc. 
If t he nee d f or c o nc o mita nt me dicat i o n ( ot her t ha n aceta mi n o p he n) arises, i ncl usi o n or 
c o nti n uat i o n of t he parti ci pa nt ma y be at t he discreti o n of t he i n vesti gat or after c o ns ultati o n wit h 
a Lill y  cl i nical  p har mac ol o gi st or cli nical researc h p h ysicia n ( C R P). 
A n y me dicat i o n use d d uri n g t he c o urse of t he st u d y m ust be d oc u me nte d. 
All vacci nes are pr o hi bite d u nt il st u d y  c o m pleti o n. 
6. 6. D ose M o dific ati o n 
De pe n di n g o n t he res ults of a gi ve n trial- le vel  s af et y  re vie w, t he d ose of t he s u bse q ue nt c o h ort (s) 
ma y be a dj ust e d . Beca use t hese a dj ust me nts t o d ose le vels are all o wa ble c ha n ges per mitte d b y 
t h e pr ot oc ol, t he y  w o ul d n ot re q ui re a pr ot oc ol  a me n d me nt. 
6. 6. 1. D ose -Esc al ati o n Criteri a 
B y  n at ure of bei n g a P hase 1 s p o ns or u n bli n de d d ose -escalat i o n st u d y , data will  b e e val uate d o n 
a n o n g o i n g basis u ntil t he hi g hest pla n ne d d ose has bee n a d mi nistere d. 
After at l east 7 parti ci pa nts ha ve c o m p le t e d D a y  4 i n a gi ve n c o h ort, all safet y data u p t o t his 
c ut off date will be re vie we d t o deter mi ne w het her t he ne xt c o h ort ca n be ra n d o mize d after 
a gree m e nt bet wee n Lill y’s me dical m o nit or a n d t he i n vest i gat or. Safet y a n d t olera bilit y data will  
be t he pri ma r y  cri t eri a g ui di n g d ose escalati o n .
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
3 2 T he i n vest i gat or a n d t he Lill y s p o ns or tea m are res p o nsi ble f or deter mi ni n g a n y d ose decisi o ns. 
T he i n vest i gat or(s) will re mai n bli n de d a n d t he Lill y s p o ns or tea m will be u n bli n de d d uri n g t hese 
re vie ws. All a vaila ble data fr o m pre vi o us c o h orts will be re vie we d. 
If te m p orar y  st o p pi n g cri t eri a are m et ( Secti o n 6. 6. 3 ), d osi n g will be te m p oraril y  h al te d a n d n o 
f urt her partici pa nts will be d ose d u ntil a f ull safet y re vie w of t he st u d y has ta ke n place . 
6. 6. 2. Access t o D at a d uri n g t he St u d y 
A li mite d n u m ber of u n bli n de d Lill y st u d y  tea m  pers o n nel will ha ve access t o safet y a n d/ or P K 
data d uri n g t he st u d y .
6. 6. 3. Te m p or ar y St o p pi n g Cr iteri a 
D osi n g will be te m p oraril y halte d, a n d n o f urt her partici pa nts will be d ose d u nt il safet y data 
a vaila ble at t hat p oi nt ha ve bee n re vie w e d ,if 
3 or m ore parti ci pa nts de vel o p A Es t hat are c o nsi dere d t o be relate d t o st u d y  treat m e nt 
a n d gra de d as at l e ast m o derate, cli nicall y si g nifica nt ,a n d n ot res p o nsi ve t o s u p p orti ve 
care .
1 or m ore parti ci pa nts de vel o p A Es t hat are c o nsi dere d t o be relate d t o st u d y  treat m e nt 
a n d t hat are seri o us ( seri o us a d verse e ve nts [ S A Es ]) or gra de d as se vere. 
T his ta ble desc ri bes t he l o c ati o n of  A E- r el ate d i nf o r m at i o n i n t his pr ot oc ol. 
T o pic L oc ati o n 
D AI D S ta ble descri bi n g se verit y of reacti o ns Secti o n 6. 1. 1. 2 
Defi niti o n of A Es Secti o n 1 0. 3. 1 
Assess me nt of I nte nsit y/ Se verit y Secti o n 1 0. 3. 3 
C ha n ges t o t he pla n ne d d osi n g sc he d ule m ust be a p pr o priatel y d oc u me nte d a n d c o m m u nicate d 
wi t h  t he st u d y  pers o n nel a n d t he i nst it uti o nal  re vie w b oar d ( I R B)/ i n de pe n de nt et hics c o m mittee 
(I E C )bef ore d osi n g c o nti n ues. 
6. 7. I nter ve nti o n after t he E n d of t he St u d y 
N ot a p plica ble. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
3 3 7. Disc o nti n u ati o n of St u d y I nter ve nti o n a n d P artici p a nt 
Disc o nti n u ati o n/ Wit h dr a w al 
T hese secti o ns descri be reas o ns f or a partici pa nt’s 
p er m a ne nt or te m p orar y  disc o nt i n uat i o n of st u d y  dr u g, or 
di sc o nti n uat i o n ( wi t h dra wal) fr o m  t he st u d y .
Di sc o nti n uati o n of  s pecific sites or of t he trial as a w h o le are ha n dle d as part of re g ulat or y, 
et hi cal, a n d trial o versi g ht c o nsi derat i o ns i n Sect i o n 1 0. 1 A p pe n di x 1. 
7. 1. Disc o nti n u ati o n of St u d y I n ter ve nti o n 
I n rare i nsta nces, it ma y be necessar y  f or a parti ci pa nt t o per m a ne nt l y disc o nt i n ue st u d y  
i nt er ve nt i o n. If t he I V i nf usi o n is per ma ne nt l y st o p pe d, t he partici pa nt will re mai n i n t he st u d y  
f o r f o ll o w- u p a n d f urt her e val uat i o ns as de scri be d i n t he S o A. 
7. 2. P artici p a nt Disc o nti n u ati o n/ Wit h dr a w al fr o m t he St u d y 
A parti ci pa nt ma y wi t h dra w fr o m  t he st u d y 
●at a n y  ti me at his/ her o w n re q uest 
●at t he re q uest of his/ her desi g nee (f or e xa m ple, pare nts or le gal g uar dia n) 
●at t he discreti o n of t he i n vest i gat or f or safet y,  be ha vi or al , c o m plia nce, or 
a d mi nistrati ve reas o ns 
●if t he partici pa nt bec o me s pre g na nt d uri n g t he st u d y 
●if e nr o ll me nt i n a n y ot her cli nical st u d y i n v o l vi n g a n i n vest i gat i o nal pr o d uct or 
e nr o ll me nt i n a n y ot her t y pe o f me d ical researc h j u d ge d n ot t o be scie nt ificall y or 
me dicall y c o m pat i ble wit h t his st u d y 
At  t he ti me of disc o nt i n ui n g fr o m t he st u d y , if  p ossi ble, a n earl y disc o nt i n uat i o n visit s h o ul d be 
c o n d ucte d, as s h o w n i n t he S oA. See S o A f or data t o be c ollecte d at t he ti me of st u d y  
di sc o nti n uat i o n a n d f o ll o w- u p a n d f or a n y  f urt her e val uat i o ns t hat nee d t o be c o m plete d .T he 
parti ci pa nt will be per ma ne nt l y disc o nt i n ue d b ot h fr o m t h e st u d y  i nt er ve n ti o n a n d fr o m t h e st u d y  
at t hat ti me .
If t he parti ci pa nt wi t h dra ws c o nse nt f o r discl os ur e of  f ut ure i nf or m at i o n, t he s p o ns or m a y  retai n 
a n d c o nt i n ue t o use a n y data c ollecte d bef ore s uc h a wit h dra wal o f c o nse nt .If a partici pa nt 
wi t h dra ws fr o m t h e st u d y , h e/s he ma y  re q uest destr ucti o n of  a n y sa m ples ta ke n a n d n ot teste d ,
a n d t he i n vest i gat or m ust d oc u me nt t his i n t he site st u d y rec or ds .
7. 2. 1. Disc o nti n u a ti o n of I n a d verte ntl y E nr olle d P artici p a nts 
If t he s p o ns or or i n vest i gat or i de nt ifies a partici pa nt w h o di d n ot meet e nr oll me nt criteria a n d 
was i na d verte ntl y e nr olle d, t he n t he partici pa nt s h o ul d be disc o nti n ue d fr o m st u d y  treat m e nt a n d 
safet y f o ll o w- u p s h o ul d be perf or m e d as o utli ne d i n 
Secti o n 1. 3 (S o A ), 
Secti o n 8. 2 ( Safet y Assess me nts), a n d 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
3 4 Secti o n 8. 3 ( A d verse E ve nts a n d Seri o us A d verse E ve nts). 
7. 3. L ost t o F oll o w - u p 
A partici pa nt will be c o nsi dere d l ost t o f oll o w -u p if  h e or s he re peate dl y fails t o ret ur n f or 
sc he d ule d visits a n d is u na ble t o be c o ntacte d b y  t he st u d y  si t e. Si te pers o n nel are e x pecte d t o 
ma ke dili ge nt atte m pts t o c o ntact partici pa nts w h o fail t o ret ur n f or a sc he d ule d visit or were 
ot her wi se u na ble t o be f o ll o we d u p b y t he site. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
3 5 8. St u d y Assess me nts a n d Pr oce d ures 
St u d y  pr oce d ures a n d t heir ti mi n g are s u m marize d i n t he S o A ( Secti o n 1. 3 ). 
I m me diate safet y c o ncer ns s h o ul d be disc usse d wit h t he s p o ns or i m me d iatel y u p o n occ urre nce or 
a ware ness t o deter mi ne if t he partici pa nt s h o ul d c o nt i n ue or disc o nt i n ue st u d y  i nt er ve nt i o n. 
A d here nce t o t he st u d y  desi g n re q ui re me nts, i ncl u di n g t h ose s pecifie d i n t he S o A, is esse nt ia l 
a n d re q uire d f or st u d y  c o n d uct. 
All scree ni n g e val uat i o ns m u st be c o m plete d a n d re vie we d t o c o nfir m t hat p ote nti al  part ic i pa nt s 
meet all eli gi bilit y cri teria. T he i n vest i gat or or desi g nee will  m ai ntai n a scree ni n g l o g t o rec or d 
details o f all parti ci pa nt s scree ne d a n d t o c o nfir m eli gi bilit y or rec or d reas o ns f or sc ree ni n g 
fail ure, as a p plica ble. 
8. 1. Effic ac y Assess me nts 
N ot a p plica ble. 
8. 2. S afet y Assess me nts 
Pl a n ne d ti me p o i nt s f or all safet y assess me nts are pr o vi de d i n t he S o A. 
8. 2. 1. Vit al Si g ns 
F or eac h parti ci pa nt , vi t al  s i g n meas ure me nts s h o ul d be c o n d ucte d acc or di n g t o t he S o A 
( Secti o n 1. 3 ). A d dit i o nal vital si g ns ma y be meas ure d d uri n g eac h st u d y  p eri o d at t he 
i n vesti gat or ’s j u d g me nt .Bl o o d press ure a n d p ulse rate s h o ul d be meas ure d after at least 
5mi n utes s u pi ne. 
Ort h ostatic vital si g ns s h o ul d be assesse d, if p ossi ble, d uri n g a n y A E of dizzi ness or 
p ost ure -i n d uce d s y m pt o ms. If ort h ostatic meas ure me nts are re q uire d, parti ci pa nts s h o ul d be 
s u pi ne f or at least 5 mi n utes a n d sta n d f or at least 3 mi n utes. If t he parti ci pa nt feels u na ble t o 
sta n d, s u pi ne vital si g ns o nl y will be rec or de d. 
A d dit i o nal vit al si g ns ma y be m eas ure d d uri n g eac h st u d y  p eri o d if warra nte d .
8. 2. 2. Electr oc ar di o gr a ms 
Si n gle 1 2 -lea d E C G rea di n gs will be o btai ne d as o utli ne d i n t he S o A (see Secti o n 1. 3 ). 
Electr ocar di o gra ms s h o ul d be rec or de d bef ore c ollecti n g a n y bl o o d f or safet y or P K tests. 
S u bjects m ust be s u pi ne f or a p pr o xi matel y  5 t o 1 0 mi n utes bef ore E C G c ollect i o n a n d re mai n 
s u pi ne b ut a wa ke d uri n g E C G c ollect i o n. 
Pa per c o pi es of all E C Gs rec or de d s h o ul d be st ore d at t he i n vest i gat i o nal si t e. 
Electr ocar di o gra ms ma y be o btai ne d at a d di ti o nal ti mes, w he n dee me d cli nicall y necessar y .
C ollect i o n of a d dit i o nal E C Gs at a partic ular ti me p oi nt is all o we d t o e ns ure hi g h -q uali t y  
rec or ds. El ectr ocar di o gra ms will  b e i nter prete d b y  a q ualifie d p h ysicia n (t he i n vesti gat or or 
q ualifie d desi g nee) at t he st u d y  si te as s o o n after t he ti me of E C G c ollect i o n as p ossi ble, a n d 
i deall y w hile t he s u bject is st ill prese nt, t o deter mi ne w het her t he s u bject meets e ntr y  cri t eri a at 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
3 6 t h e rel e va nt vi si t(s) a n d f or i m me diate s u bject ma na ge me nt, s h o ul d a n y cl i nicall y  rele va nt 
fi n di n gs be i de nt ifie d. 
A n y cli nicall y  si g nifica nt fi n di n gs fr o m E C Gs t hat res ult i n a dia g n osis a n d t hat occ ur after t he 
s u bject recei ves t he i n vest i gat i o nal pr o d uct s h o ul d be re p orte d t o Lill y, or its desi g nee, as a n A E 
via t h e e C R F. 
8. 2. 3.  Cli nic al S afet y L a b or at or y Assess me nts 
See Secti o n 1 0. 2 , A p pe n di x 2 f or t he list of cli nical la b orat or y tests t o be perf or me d a n d t o t he 
S o A f or t he ti mi n g a n d fre q ue nc y. 
All pr ot oc ol -re q ui re d la b orat or y  assess me nts, as defi ne d i n A p pe n di x 2, m ust be c o n d ucte d i n 
acc or da nce wit h t he la b orat or y  m a n ual a n d t he S o A. 
T he i n vest i gat or m ust re vie w t he la b orat or y re p ort, d oc u me nt t his re vie w, a n d r ec or d a n y  
cli nicall y rele va nt c ha n ges occ urri n g d uri n g t he st u d y  i n t he A E secti o n of t he C R F. T he 
la b orat or y  re p orts m ust be file d wit h t he s o urce d oc u me nts .
If la b orat or y  v al ues fr o m n o n pr ot oc ol -s pecifie d la b orat or y  assess me nts perf or m e d at t he 
i nst it uti o n’s l o c al  l a b orat or y  r e q ui re a c ha n ge i n parti ci pa nt m a na ge me nt or are c o nsi dere d 
cli nicall y si g nifica nt b y  t he i n vesti gat or (e . g. , S A E or A E or d ose m o dificat i o n), t he n t he res ul ts 
m ust be rec or de d i n t he C R F. 
8. 2. 4. He p atic M o nit ori n g 
Cl ose he p atic m o nit ori n g 
La b orat or y  tests ( A p pe n di x 6, Secti o n 1 0. 6 ), i ncl u di n g A L T, A S T, A L P, T B L, D. Bil, G G T, a n d 
C K, s h o ul d be re peate d wi t hi n 4 8 t o 7 2 h o urs t o c o nfir m t he a b n or malit y a n d t o deter mi ne if it is 
i ncreasi n g or decreasi n g, if o ne or m ore of t hese c o n dit i o ns occ ur: 
If a partici pa nt wit h baseli ne res ults of ... de vel o ps t he f oll o wi n g ele vati o ns: 
A L T or A S T < 1. 5 x U L N A L T or A S T ≥ 3 x U L N 
A L P < 1. 5 x U L N A L P ≥ 2 x U L N 
T B L < 1. 5 x U L N T B L ≥ 2 x U L N (e xce pt f or patie nts wit h Gil bert’s s y n dr o me) 
A L T or A S T ≥ 1. 5 x U L N A L T or A S T ≥ 2 x baseli ne 
A L P ≥ 1. 5 x U L N A L P ≥ 2 x baseli ne 
T B L ≥ 1. 5 x U L N T B L ≥ 2 x baseli ne (e xce pt f or patie nts wit h Gil bert’s s y n dr o me) 
If t he a b n or malit y persists or w orse ns, cli nical a n d la b orat or y  m o ni t ori n g, a n d e val uat i o n f o r 
p ossi ble ca uses of a b n or mal li ver tests s h o ul d be i nit iate d b y  t he i n vest i gat or i n c o ns ultat i o n wi t h  
t h e Lill y -desi g nate d m e dical m o nit or. At a mi ni m u m, t his e val uat i o n s h o ul d i ncl u de p h ysical 
e xa mi nat i o n a n d a t h or o u g h me dical hist or y , i ncl u di n g s y m pt o m s, rece nt ill nesses (f or e xa m ple, 
heart fail ure, s yste mic i nfect i o n, h y p ote nsi o n, or seiz ures), rece nt tra vel, hist or y  of  c o nc o mi t a nt 
me dicat i o ns (i ncl u di n g o ver -t h e- c o u nter), her bal a n d dietar y  s u p ple me nts, hist or y  of  al c o h o l 
dri n ki n g a n d ot her s u bsta nce a b use .
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
3 7 I ni ti all y, m o ni t ori n g of  s y m pt o ms a n d he pat ic bi oc he mical te sts s h o ul d be d o ne at a fre q ue nc y o f 
1 t o 3 ti mes wee kl y , base d o n t he parti ci pa nt’s cli nical c o n dit i o n a n d he pat ic bi oc he mical tests. 
S u bse q ue ntl y, t he fre q ue nc y  of  m o ni t ori n g m a y be l o were d t o o nce e ver y  1 t o 2 wee ks, if t he 
parti ci pa nt’s cli nical c o n dit i o n a n d l a b res ul ts sta bilize. M o ni t ori n g of A L T, A S T, A L P, a n d 
T B L s h o ul d c o nt i n ue u nt il le vels n or malize or ret ur n t o a p pr o xi mate baseli ne le vels. 
C o m pre he nsi ve he p atic e v al u ati o n 
A c o m pre he nsi ve e val uat i o n s h o ul d be perf or m e d t o searc h f or p ossi ble ca uses of li ver i nj ur y  i f 
o ne or m ore of t hese c o n dit i o ns occ ur: 
If a partici pa nt wit h baseli ne 
res ults of... de vel o ps t he f oll o wi n g ele vati o ns: 
A L T or A S T < 1. 5 x U L N A L T or A S T ≥ 3 x U L N wit h he patic si g ns/s y m pt o ms *, or 
A L T or A S T ≥ 5 x U L N 
A L P < 1. 5 x U L N A L P ≥ 3 x U L N 
T B L < 1. 5 x U L N T B L ≥ 2 x U L N (e xce pt f or patie nts wit h Gil bert’s s y n dr o me) 
A L T or A S T ≥ 1. 5 x U L N A L T or A S T ≥ 2 x baseli ne wit h he patic si g ns/s y m pt o ms *, or 
A L T or A S T ≥ 3 x baseli ne 
A L P ≥ 1. 5 x U L N A L P ≥ 2 x baseli ne 
T B L ≥ 1. 5 x U L N T B L ≥ 1. 5 x baseli ne (e xce pt f or patie nts wit h Gil bert’s s y n dr o me) 
* He patic si g ns/s y m pt o ms are se vere fati g ue, na usea, v o miti n g, ri g ht u p per q ua dra nt a b d o mi nal pai n, fe ver, ras h, 
a n d/ o r e osi n o p hilia > 5 %. 
At  a mi ni m u m, t his e val uat i o n s h o ul d i ncl u de p h ysical e xa mi nat i o n a n d a t h or o u g h me dical 
hist or y , as o utli ne d a b o ve, as well as tests f or P T -I N R; tests f or viral he pat it is A, B, C, or E; tests 
f o r a ut oi m m u ne he patit is; a n d a n a b d o mi nal i ma gi n g st u d y  (f or e xa m ple, ultras o u n d or C T 
sca n). 
Base d o n t he patie nt’s hist or y  a n d i ni ti al res ul ts, f urt her testi n g s h o ul d be c o nsi dere d i n 
c o ns ultati o n wit h t he Lill y -desi g nate d m e dical m o ni t or, i ncl u di n g tests f or he patit is D vir us 
( H D V), c y t o m e gal o vi r us ( C M V), E pstei n- Barr vi r us ( E B V), aceta mi n o p he n le vels, 
aceta mi n o p he n pr otei n a d d ucts, uri ne t o xic o l o g y  scree n, Wils o n’s disease, bl o o d alc o h o l le vels, 
uri nar y  et h yl  gl uc ur o ni de, a n d ser u m p h os p hat i d ylet ha n o l.  Base d o n t he circ u msta nces a n d t he 
i n vesti gat or’s assess me nt of  t he parti ci pa nt’s cli nical c o n dit i o n, t he i n vesti gat or s h o ul d c o nsi der 
referri n g t he partici pa nt f or a he pat ol o gist or gastr oe nter ol o gist c o ns ultati o n, ma g net ic res o na nce 
c h o la n gi o pa ncreat o gra p h y  ( M R C P), e n d osc o pi c retr o gra de c h ola n gi o pa ncreat o gra p h y  ( E R C P), 
car di ac ec h ocar di o gr a m , or a li ver bi o ps y. 
A d diti o n al he p atic d at a c ollecti o n ( he p atic s afet y C R F) i n st u d y p artici p a nts w h o h a ve 
a b n or m al li ver tests d uri n g t he st u d y 
A d dit i o nal he patic safet y data c ollect i o n i n he pat ic  safet y case re p ort f or ms ( C R F) s h o ul d be 
perf or m e d i n st u d y  p arti ci pa nts w h o meet 1 or m ore of t he f o ll o wi n g 5 c o n di ti o ns: 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
3 8 1. Ele vat i o n of ser u m A L T t o ≥ 5 x U L N o n 2 or m ore c o nsec uti ve bl o o d tests (if baseli ne A L T 
< 1. 5 x U L N) 
I n parti ci pa nts wi t h  baseli ne A L T ≥ 1. 5 x U L N, t he t hres h o l d is A L T ≥ 3 x baseli ne o n 2 
or m ore c o nsec uti ve tests 
2. Ele vate d T B L t o ≥ 2 x U L N (if baseli ne T B L < 1. 5 x U L N) (e xce pt f or cases of k n o w n 
Gil bert’s s y n dr o me) 
I n parti ci pa nts wi t h  baseli ne T B L ≥ 1. 5 x U L N, t h e t hres h o l d s h o ul d be T B L ≥ 2 x 
baseli ne 
3. Ele vat i o n of ser u m A L P t o ≥ 2 x U L N o n 2 or m ore c o nsec uti ve bl o o d tests (if baseli ne A L P 
< 1. 5 x U L N) 
I n parti ci pa nts wi t h  baseli ne A L P ≥ 1. 5 x U L N, t he t hres h o l d is A L P ≥ 2 x baseli ne o n 2 
or m ore c o nsec uti ve bl o o d tests 
4. He pati c e ve nt c o nsi dere d t o be a seri o us a d verse e ve nt ( S A E) 
5. Di sc o nti n uati o n of  st u d y  dr u g d ue t o a he pati c e ve nt .
N ote: t he i nter val bet wee n t he t w o c o nsec uti ve bl o o d tests s h o ul d be at least 2 da y s. 
8. 3. A d verse E ve nts a n d Seri o us A d verse E ve nts 
Ad verse e ve nt swill be re p orte d b y  t he parti ci pa nt. 
T he i n vest i gat or a n d a n y q ualifie d desi g nees are res p o nsi ble f or detecti n g, d oc u me nti n g, a n d 
rec or di n g e ve nts t hat meet t he defi nit i o n of a n A E or S A E a n d re mai n res p o nsi ble f or f o ll o wi n g 
u p A Es t hat are seri o us, c o nsi dere d relate d t o t he st u d y  i nt er ve nt io n or st u d y  pr oce d ures, or t hat 
ca use d t he partici pa nt t o disc o nt i n ue t he st u d y  i nt er ve nt i o n or st u d y .
Di sc o nti n uati o n i nf or mat i o n is i n Sect i o n 7.
Detaile d A E defi nit i o ns a n d pr oce d ures are i n Secti o n 1 0. 3 .
8. 3. 1. Ti me Peri o d a n d Fre q ue nc y f or C ollecti n g A E a n d S A E I nf or m ati o n 
All A Es a n d S A Es will be c ollecte d fr o m t he ti me of si g ni n g of  t he I C F u nt il part ic i pat i o n i n t he 
st u d y  h as e n de d .
A d verse e ve nts t hat be gi n bef ore t he start of st u d y  i nt er ve nt i o n b ut after si g ni n g of t he I C F will 
be rec or de d o n t he A d verse E ve nt C R F. 
Alt h o u g h all A Es after si g ni n g t he I C F are rec or de d b y  t he si te i n t he C R F/electr o ni c data e ntr y , 
S A E re p orti n g t o s p o ns or be gi ns after t he partici pa nt has si g ne d t he I C F a n d has recei ve d st u d y  
i nt er ve nt i o n. H o we ver, if a n S A E occ urs after si g ni n g t he I C F, b ut pri or t o recei vi n g st u d y  
i nt er ve nt i o n, i t nee ds t o be re p orte d wit hi n t he S A E re p orti n g t i me fra me if it is c o nsi dere d 
reas o na bl y  p ossi bl y  relate d t o st u d y  pr oce d ures. 
All S A Es will be rec or de d a n d re p orte d t o t he s p o ns or or desi g nee i m me diatel y a n d u n der n o 
ci rc u msta nce s h o ul d t hi s e xcee d 2 4 h o urs, as i n dicate d i n Secti o n 1 0. 3 , A p pe n di x 3. T he 
i n vesti gat or will s u b mit a n y  u p date d S A E data t o t he s p o ns or wit hi n 2 4 h o urs of it bei n g 
availa ble. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
3 9 I n vest i gat ors are n ot o bli gate d t o acti vel y see k A Es or S A Es aft er c o ncl usi o n  of  t he st u d y  
parti ci pat i o n. H o we ver, if t he i n vest i gat or lear ns of a n y S A E, i ncl u di n g a deat h, at a n y t i me after 
a partici pa nt has bee n disc har ge d fr o m t he st u d y , a n d he/s he c o nsi ders t he e ve nt t o be reas o na bl y  
r el ate d t o t he st u d y  i nt er ve nt i o n or st u d y  p arti ci pati o n , t he i n vest i gat o r m ust pr o m pt l y n otif y  t h e 
s p o ns or. 
8. 3. 2. Met h o d of Detecti n g A Es a n d S A Es 
T he m et h o d of rec or di n g, e val uat i n g, a n d assessi n g ca usalit y of A E a n d S A E a n d t he pr oce d ures 
f o r c o m plet i n g a n d tra ns mitt i n g S A E re p orts are pr o vi de d i n Sect i o n1 0. 3 .
Care will be ta ke n n ot t o i ntr o d uce bias w h il e detecti n g A Es a n d/ or S A Es. O pe n -e n de d a n d 
n o nlea di n g ver bal q uesti o ni n g of t he partici pa nt is t he preferre d met h o d t o i n q uire a b o ut A E 
occ urre nces .
8. 3. 3. F oll o w -u p of A Es a n d S A Es 
After t he i nit ial A E/ S A E re p ort, t he i n vesti gat or is re q uire d t o pr oacti vel y f o ll o w eac h partici pa nt 
at s u bse q ue nt visits/c o ntacts. All S A Es will be f o ll o we d u p u ntil res o l ut i o n, sta bilizat i o n, t he 
e ve nt i s ot her wise e x plai ne d, or t he partici pa nt is l ost t o f o ll o w- u p (as de fi ne d i n Secti o n 7. 3 ). 
F urt her i nf or mat i o n o n f o ll o w- u p pr oce d ures i s pr o vi de d i n Sect i o n 1 0. 3 .
8. 3. 4. Re g ul at or y Re p orti n g Re q uire me nts f or S A Es 
Pr o m pt n otificat i o n b y t he i n vest i gat or t o t he s p o ns or of a nS A E is esse nt ia l s o t hat l e g al  
o bli gat i o ns a n d et hical res p o nsi bilit ies t o war d t he safet y of  p arti ci pa nts a n d t he safet y of  a st u d y  
i nt er ve nt i o n u n der cli nical i n vesti gat i o n are m et. 
T he s p o ns or has a le gal res p o nsi bilit y t o n otif y b ot h t he l o c al  re g ulat o r y  a ut h ori t y  a n d ot her 
re g ul at or y  a ge ncies a b o ut t he safet y of  a st u d y  i nt er ve nt i o n u n der cli nical i n vesti gati o n. T he 
s p o ns or will c o m p l y wi t h  c o u ntr y -s pecific re g ulat or y  r e q ui re me nts relati n g t o safet y re p orti n g t o 
t h e re g ulat or y  a ut h ori t y , I R B/I E C , a n d in vest i gat ors. 
A n i n vest i gat or w h o recei ves a n i n vest i gat or safet y re p ort descri bi n g a nS A E or ot her s pecific 
safet y i nf or mat i o n (e. g., s u m mar y  or list i n g of S A Es) fr o m t he s p o ns or will re vie w a n d t he n file 
it  wi t h  t he I B, a n d will n otif y  t he I R B/I E C, if a p pr o pri ate acc or di n g t o l o c al  r e q ui re me nts. 
8. 3. 5. Pre g n a nc y 
Details o f all pre g na ncies i n fe male partici pa nts a n d fe male part ners of male parti ci pa nts will be 
c ollecte d after t he start of st u d y  i nt er ve nt i o n a n d u nt il at l east 5 m o nt hs after t he l ast d ose .
If a pre g na nc y  i s re p orte d, t he i n vesti gat or s h o ul d i nf or m t he s p o ns or wit hi n 2 4 h o urs of  l ear ni n g 
of  t he pre g na nc y  a n d s h o ul d f ol l o w t he pr oce d ures o utli ne d i n Sect i o n1 0. 4 .
A b n or m al  pre g na nc y o utc o m es (e . g ., s p o nta ne o us a b orti o n, fet al  deat h, still birt h, c o n ge nital 
a n o ma lies, ect o pi c pre g na nc y ) are c o nsi dere d S A Es. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
4 0 8. 3. 6. H y perse nsiti vit y Re acti o ns 
Ma n y  dr u gs, b ut parti c ularl y bi o l o gic a ge nts, carr y t he ris k of s yste mic h y perse nsit i vit y 
reacti o ns. If s uc h a reacti o n occ urs, a d dit i o nal detail s descri bi n g eac h s y m pt o m s h o ul d be 
pr o vi de d t o t he s p o ns or i n t he i nf usi o n- relate d reacti o n/ h y perse nsit i vit y C R F. 
If s y m pt o ms a n d/ or si g ns occ ur d uri n g or wit hi n 6h o urs after e n d of i nf usi o n of L Y 3 8 3 2 4 7 9 a n d 
are belie ve d t o be h y perse nsi ti vi t y  or d ue t o c y t o ki ne release, t he n i n vesti gat ors are e nc o ura ge d 
t o re p ort t he e ve nt as i nf usi o n- r el ate d i m me diate h y perse nsit i vit y react i o n or c y t o ki ne rel ease -
ass oci ate d i nf usi o n  reacti o n, res pect i vel y. 
Si tes s h o ul d ha ve a p pr o pri atel y  trai ne d me dical  pers o n nel a n d a p pr o pri ate me dical e q ui p me nt 
a vaila ble w he n st u d y  p arti ci pa nts are recei vi n g i nter ve nt i o n. It i s rec o m me n de d t hat partici pa nts 
w h o e x perie nce a s yste mic h y perse nsit i vit y react i o n be treate d per nati o nal a n d i nter nat i o nal 
g ui da nce ( Lie ber ma n et al 2 0 1 5; Si m o n s et al . 2 0 1 5) 
I n t he case of ge neralize d urticaria or a na p h yla xis, a d dit i o nal bl o o d a n d uri ne sa m ples s h o ul d be 
c ollecte d as descri be d i n Secti o n 1 0. 7 ,A p pe n di x 7, “ Rec o m me n de d La b orat or y  Testi n g f or 
H y perse nsi ti vi t y  E ve nts”. La b orat or y res ults are pr o vi de d t o t he s p o ns or via t he ce ntral 
la b orat or y . 
8. 3. 7. S A R S - C O V- 2 I nfecti o n 
I n t he e ve nt of a s u s pecte d S A R S -C o V -2 i nfect i o n, parti ci pa nts will u n der g o a vi r al  t est usi n g 
nasal or nas o p har y n geal s wa b a n d be m a na ge d acc or di n g t o sta n dar d of care. 
S us pi ci o n  of  S A R S -C o V -2 i nfect i o n, i n t he o pi ni o n of t he i n vesti gat or, will rel y u p o n 
a rece nt e x p os ure t o S A R S -C o V -2 defi ne d as: 
oli vi n g i n t he sa me h o use h o l d as a pers o n wit h S A R S -C o V - 2 ;
oha vi n g ha d direct p h ysical c o ntact wit h a pers o n wit h S A R S -C o V -2 (e. g. s ha ki n g 
ha n ds); 
oha vi n g u n pr otecte d direct c o n tact wi t h  i nfect i o us secreti o ns of  a pers o n wi t h  
S A R S -C o V- 2 (e. g. bei n g c o u g he d o n, t o uc hi n g use d pa per tiss ues wit h a bare 
ha n d); 
oha vi n g ha d face -t o -face c o ntact wit h a pers o n wit h S A R S -C o V -2, wit hi n 2 m a n d 
f o r m ore t ha n 1 5 mi n utes. 
a n d/ or si g ns or s y m pt o m s t hat, i n t he o pi ni o n o f t h e i n vest i gat or, are s u g ges ti ve of S A R S -
C o V -2 i nfect i o n (e. g., fe ver, dr y  c o u g h, s h ort ness of breat h, h y p o xia, etc.) 
I n a d dit i o n, S A R S -C o V - 2 p oi nt -of -care tests ma y be perf or m e d at s pecific t i me p o i nt s d uri n g t he 
st u d y  at t he di screti o n of  t he i n vest i ga t or. E ver y  ti me s uc h a p oi nt -of -care test i s perf or m e d p ost 
baseli ne, a n a d dit i o n al  nasal or nas o p har y n geal s wa b sa m ple ma y be c ollecte d i n parallel, f o r 
researc h p ur p oses s uc h as viral se q ue nci n g. T hi s researc h s wa b sa m ple will be s hi p pe d t o t he 
s p o ns or o nl y  if  t h e p oi nt -of -care test is p osi ti ve. If t he p oi nt -of -care test i s ne gat i ve, t he researc h 
s wa b sa m ple s h o ul dbe discar de d.   
If a n y partici pa nt is teste d p ositi ve p ost baseli ne, pri or t o t his pr ot oc ol a me n d me nt bei n g 
a p pr o ve d, a n a d dit i o nal nasal or nas o p har y n geal s wa b sa m ple ma y be c ollecte d f or researc h 
p ur p oses .
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
4 1 8. 3. 8. I nf usi o n - R el ate d Re acti o ns 
As wi t h  ot her m A bs, i nf usi o n- relate d reacti o ns ma y  occ ur d uri n g or f oll o wi n g L Y 3 8 3 2 4 7 9 
a d mi nistrati o n .If a n i nf usi o n- relate d reacti o n occ urs, a d dit i o nal data descri bi n g eac h s y m pt o m 
a n d si g n s h o ul d be pr o vi de d t o t he s p o ns or i n t he C R F. 
T his ta ble descri bes t he l ocati o n of i nf usi o n- r el ate d reacti o n i nf or m at i o n i n t his pr ot oc ol. 
T o pic L oc ati o n 
S pecial treat me nt c o nsi derati o ns Secti o n 6. 1. 1 
Ma na ge me nt of i nf usi o n reacti o ns Secti o n 6. 1. 1. 2 
D AI D S ta ble descri bi n g se verit y Sec ti o n 6. 1. 1. 2 
Treat me nt g ui deli nes f or i nf usi o n -relate d reacti o ns Secti o n 6. 1. 1. 2 
S y m pt o m s occ urri n g d uri n g or after i nf usi o n of st u d y  i nt er ve nt i o nma y als o be defi ne d acc or di n g 
t o A E cate g ories s uc h as ac ute aller gic reacti o n or c y t o ki ne release s y n dr o me ( r ef er t o D AI D S ). 
8. 3. 9. Pr o d uct C o m pl ai nts 
A pr o d uct c o m plai nt is a n y writte n, electr o nic, or oral c o m m u nicat i o n t hat alle ges deficie ncies 
r el ate d t o t he i de ntit y,  q ualit y, d ura bilit y,  relia bilit y,  s af et y,  effect i ve ness ,or perf or ma nce of a 
tri al  i nt er ve nt i o n. 
T he s p o ns or c o lle cts pr o d uct c o m plai nts o n st u d y  i nter ve nt i o ns use d i n cli nical st u dies t o e ns ure 
t h e safet y of  st u d y  p arti ci pa nts, m o ni t or q ualit y, a n d t o facilitate pr ocess a n d pr o d uct 
i m pr o ve me nts. 
P arti ci p a nts will be i nstr ucte d t o c o ntact t he i n vest i gat or as s o o n as p ossi ble if t h e y ha ve a 
c o m plai nt or pr o bl e m wi t h  t he st u d y  i nt er ve nt i o ns o t hat t he si t u ati o n ca n be assesse d. 
N O T E: A n y A Es or S A Es t hat are ass ociate d wit h a pr o d uct c o m plai nt will f o ll o w t he pr ocesses 
o utli ne d i n Sect i o n 8. 3. 3 a n d A p pe n di x 1 0. 3 of  t he pr ot oc ol. 
Ti me Peri o d f or Detecti n g Pr o d uct C o m pl ai nts 
Pr o d uct c o m plai nts t h at res ul t i n a n A E will be detecte d, d oc u me nte d, a n d re p orte d t o t he 
s p o ns or d uri n g all peri o ds of t he st u d y i n w hic h t he st u d y  i nt er ve nt i o n is use d. 
If t he i n v esti gat or l ear ns of a n y pr o d uct c o m plai nt at a n y  ti me after a partici pa nt has bee n 
di sc har ge d fr o m  t he st u d y , a n d s uc h i nci de nt is c o nsi dere d reas o na bl y relate d t o t h e st u d y  
i nt er ve nt i o n, t he i n vesti gat or will pr o m pt l y n otif y t he s p o ns or. 
Pr o m pt Re p orti n g of Pr o d uct C o m pl ai nts t o S p o ns or 
Pr o d uct c o m plai nts will  b e re p orte d t o t he s p o ns or wit hi n 2 4 h o urs aft er t he i n vest i gat or bec o mes 
a ware of t he c o m plai nt .
T he Pr o d uct C o m plai nt F or m  will be se nt t o t he s p o ns or b y  a m et h o d desi g nate d b y  t he s p o ns or. 
F oll o w- u p of Pr o d uct C o m pl ai nts 
F o ll o w- u p a p plies t o all partici pa nts, i ncl u di n g t h ose w h o disc o nt i n ue st u d y  i nt er ve nt i o n. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
4 2 T he i n vest i gat or is res p o nsi ble f or e ns uri n g t hat f oll o w -u p i ncl u des a n y s u p ple me ntal 
i n vesti gat i o ns as i n dicate d t o el uci date t he nat ure a n d/ or ca usalit y of  t he pr o d uct c o m plai nt .
Ne w or u p date d i nf or mat i o n will be rec or de d o n t he ori gi nall y c o m p lete d f or m wit h all c ha n ges 
si g ne d a n d date d b y t he i n vest i gat or a n d s u b mitte d t o t he s p o ns or .
8. 4. Tre at me nt of O ver d ose 
F or t he p ur p oses of t his st u d y , a n o ver d ose of L Y 3 8 3 2 4 7 9 is c o nsi dere d a n y  d ose hi g her t ha n t he 
d ose assi g ne d t hr o u g h ra n d o mizat i o n. I n case of s us pecte d o ver d ose, partici pa nts s h o ul d be 
m o nit ore d f or a n y  si g ns or s y m pt o ms of a d verse reacti o ns or effects, a n d s u p p orti ve care s h o ul d 
be pr o vi de d as necessar y .
8. 5. P h ar m ac o ki netics 
Ve n o us bl o o d sa m ples will  be c ollecte d as s pecifie d i n t he S o A f or deter mi nati o n of  s er u m  
c o nce ntrati o ns of  L Y 3 8 3 2 4 7 9 use d t o e val uate t he P K f o r L Y 3 8 3 2 4 7 9 .
A ma xi m u m of 5sa m ples m a y be c ollecte d at a d diti o nal t i me p o i nt s d uri n g t he st u d y  i f 
warra nte d a n d a gree d u p o n bet wee n t he i n vest i gat or a n d t he s p o ns or. 
I nstr ucti o ns f or t he c ollect i o n a n d ha n dli n g of bi o l o gi cal sa m ples will be pr o vi de d b y Lill y . 
Si te pers o n nel will r ec or d 
the date a n d ti me ( 2 4 -h o ur cl oc k ti me) of  a d mi nistrati o n (start a n d e n d of i nf usi o n), a n d 
the date a n d ti me ( 2 4 -h o ur cl oc k ti me) of eac h P K  sa m pl e. 
It i s esse nt ia l t hat t he ti mes are rec or de d acc uratel y .
8. 6. P h ar m ac o d y n a mics 
P har mac o d y na mic para meters a re n ot e val uate d i n t his st u d y .
8. 7. Ge netics 
A w h o le bl o o d sa m ple will be c o llecte d f or p har mac o ge net ic a nal ysis w here l ocal re g ulat i o ns 
all o w. 
See Secti o n 1 0. 2 Cli nical La b orat or y  T e sts, a n d Secti o n 1. 3 S o A f or sa m ple c o llect i o n 
i nf or m at i o n. 
See Secti o n 1 0. 5 f o r ge netic researc h, c ust o d y , a n d sa m ple rete nti o n i nf or mat i o n. 
8. 8. Bi o m ar kers 
Bl o o d sa m ples will be c ollecte d fr o m all part ic i pa nts f or a nal ysis o f i m m u ne s yste m a n d 
L Y 3 8 3 2 4 7 9 -r el at e d m ar kers. Ser u m sa m ples f or e x p l o rat or y  bi o m ar ker researc h will be 
c ollecte d at t he ti me s pecifie d i n t he S o A w here l ocal re g ulati o ns all o w. 
Sa m ples will  b e st ore d a n d a nal ysis ma y  be perf or me d o n bi o mar ker st h o u g ht t o pl a y a r ol e i n 
i m m u ne s yste m -relate d res p o nses t o viral i nfecti o nor a d mi nistrati o n o f L Y 3 8 3 2 4 7 9 i ncl u di n g, 
b ut n ot li mite d t o , i m m u ne pat h wa ys or ser u m a nal ytes t o e val uate t heir ass ociat i o n wi t h 
L Y 3 8 3 2 4 7 9 a d mi nistrati o n .
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
4 3 Sa m ples ma y  be use d f or researc h t o de vel o p met h o ds, assa ys, pr o g n ostics ,a n d/ or c o m pa ni o n 
di a g n osti cs r el ate d t o t he i nter ve nti o n tar get ( S pr otei n), pat h wa y s ass oci at e d wi t h  disease, a n d/ or 
t h e mec ha nis m of act i o n of t he st u d y  i nt er ve nt i o n. 
Pos t- baseli ne s wa b sa m ple sma y be use d f or researc h p ur p oses, s uc h as viral se q ue nci n g .
S a m ple rete nti o n is descri be d i n Sect i o n 1 0. 1. 1 0 .
8. 9. I m m u n o ge nicit y Assess me nts 
Visits a n d ti mes 
At t h e visit s a n d t i mes s pecifie d i n t he So A ,pre d ose ve n o us bl o o d s a m ples will  be c ollecte d t o 
deter mi ne a nti b o d y  pr o d u cti o n a gai nst L Y 3 8 3 2 4 7 9 .T he act ual date a n d ti me ( 2 4 -h o ur cl oc k 
ti me) of eac h sa m ple c ollecti o n will be rec or de d. T o ai d i nter pretati o n o f t h ese res ults, P K 
sa m ples will be c o llecte d at t he sa me t i me p oi nts as t he i m m u n o ge nicit y sa m ples .
S a m ple c ollecti o n, h a n dli n g, a n d use 
I nstr ucti o ns f or t he c ollect i o n a n d ha n dli n g of bl o o d sa m ples will be pr o vi de d b y t he s p o ns or. 
I m m u n o ge nicit y will  b e assesse d usi n g a vali date d assa y  desi g ne d t o detect A D As i n t he 
prese nce of L Y 3 8 3 2 4 7 9 at a la b orat or y a p pr o ve d b y  t he s p o ns or. A nt i b o dies ma y be f urt her 
c haracterize d f or t h ei r a bili t y  t o ne utralize t he act i vit y of  L Y 3 8 3 2 4 7 9 .
S a m ple rete nti o n 
S a m ple rete nti o n is descri b e d i n Sect i o n1 0. 1. 1 0 .
8. 1 0. He alt h Ec o n o mic s
N ot a p plica ble. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
4 4 9. St atistic al C o nsi der a ti o ns 
9. 1. St atistic al H y p ot heses 
T his is a n e x pl orat or y  st u d y  wi t h  a pri mar y  o bjecti ve of assessi n g safet y a n d t ol era bilit y. A n y 
h y p ot hesis tests c o n d ucte d f or treat me nt c o m paris o ns will be e x pl orat or y  i n nat ure a n d 
c o n d ucte d wit h o ut a dj ust me nt f or m ult i p licit y. 
9. 2. S a m ple Size Deter mi n ati o n 
A ma xi m u m of 3 0 parti ci pa nts will be e nr o lle d t o st u d y  i nt er ve nt i o n s uc h t hat a p pr o xi matel y 
8  parti ci pa nts ha ve s ufficie nt e val ua ble data i n eac h c o h ort .
T he sa m ple size is c ust o mar y  f or fi rst -i n -h u ma n st u dies e val uat i n g safet y a n d P K, a n d is n ot 
p o were d o n t he basis o f st ati st ical h y p ot hesis testi n g. 
F or re pl ace me nt of parti ci pa nts w h o are ra n d o mize d b ut n ot d ose d ,see Secti o n 4. 1. 1 .
9. 3. P o p ul ati o ns f or A n al yses 
The f o ll o wi n g p o p ul at i o ns are defi ne d: 
P o p ul ati o n Descri pti o n 
E ntere d All partici pa nts w h o si g n t he I C F 
S af et y All partici pa nts r a n d o ml y assi g ne d t o st u d y  i nt er ve nt i o n a n d w h o 
are a d mi nistere d at l east 1 d ose of st u d y i nt er ve nt i o n . 
P arti ci pa nts will be a nal yze d acc or di n g t o t he i nt er ve nt i o n t h e y  
act uall y recei ve d .
P har mac o ki net ic A nal ysis All ra n d o mize d partici pa nts w h o recei ve d st u d y i nter ve nt i o na n d 
ha ve baseli ne a n d ha ve m ult i p le e val ua ble P K sa m pl es. 
9. 4. St atistic al A n al yses 
Stati st ical a nal ysis o f t his st u d y  will  b e t he res p o nsi bilit y of sp o ns or or i ts desi g nee .
All tests of treat me nt effects will be c o n d ucte d at a 2-si d e d al p ha le vel of 0. 0 5 , u nl ess ot her wise 
state d, a n d all c o nfi de nce i nter vals will be gi ve n at a 2 -si de d 9 5 %le vel .
A n y c ha n ge t o t he data a nal ysis met h o ds descri be d i n t he pr ot oc ol will re q uire a n a me n d me nt 
o nl y  if  i t c ha n ges a pri nci p al  f eat ure of t he pr ot oc ol. A n y ot her c ha n ge t o t he data a nal ysis 
met h o ds descri be d i n t he pr ot oc ol, a n d t he j ust ificati o n f or ma k i n g t he c ha n ge, will be descri be d 
i n t he statist ical a nal ysis pla n (S A P )a n d t he cli nical st u d y  re p ort. A d dit i o nal e x pl orat or y  
a nal yses o f t h e data will be c o n d ucte d as dee me d a p pr o priate. 
T he S A P will be fi nalize d pri or t o u n bli n di n g a n d it will i ncl u de a m ore tec h nical a n d detaile d 
descri pt i o n of t he statist ical a nal yses descri be d i n t his secti o n. T his secti o n is a s u m mar y o f t h e 
pl a n ne d statistical a nal yses of t he m ost i m p orta nt e n d p o i nt s i ncl u di n g pri mar y  a n d ke y  sec o n dar y  
e n d p o i nt s. 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
459.4.1. General Considerations
Statistical analyses will be performed using SAS®Versi on 9. 4 or hi gher.
For continuous measures, s ummary  stati stics will include sample size , mean, standard deviat ion, 
minimum, median, and maximum. For categorical measures , summary s tatistics will include the 
sample size, frequency count , and percentage.
For all safet y analyses, baseline will be defined as the last evaluable value bef oredosing .
9.4.2. Primary Endpoint s (Safety)
All analyses of primary  endpoints will  be made on the Safet y Populati on.
All invest igational product -and protocol procedure -related AEs will be listed and, if the 
frequency  of events all ows, safet y data will be summarized using descriptive methodology .The 
incidence of symptoms for each treatment will be presented by severit y and by  associ ation with 
investigat ional product as perceived by the investigator.
A TEAE i s defined as an event that emerges after treatmen t (ie, after administrati on of  placebo 
or LY3832479), having been absent pretreatment, or worsens relat ive to the pretreatment state.
The number of participants who experience a TEAE and/or anSAE (all causalit ies and related to 
study  drug) will be summari zed by study  treatm ent. All TEAEs will be summarized by system 
organ class and by  decreasing frequency wit hin system organ class.
Other safet y param eters that will be assessed include safet y laboratory  parameters, vi tal signs, 
and ECG parameters. The param eters will be listed and summarized using summary  stati stics. 
Addit ional analysis will be performed if warranted upon review of the data.
9.4.3. Secondary Endpoint s (PK)
Pharmacokinet ic parameter estimates for LY 3832479 will be calculated using standard 
nonco mpart mental methods of analysis and summarized by  dose using descri ptive statistics , if 
sufficient data are available .
The parameters for analysis will be Cmax and AUC of LY3832479. Other noncompart mental 
param eters, such as time to Cmax, apparent terminal eliminat ion half-life, cl earance, and volume 
of distribut ion may be reported. Analyses of other PK parameters may be performed, if 
appropriate.
A compartmental analysis may also be performed to further characterize LY3832479 PK and 
support model-based PK simulat ions.
9.4.4. Tertiary/ Exploratory Endpoint (Immunogenicity)
The frequency and percentage of participants with preexist ing ADA and treatm ent-emergent 
(TE)ADA+ to LY3832479 will be tabulated. Treatment -emergent ADA+ isdefined as those 
with atiter 2-fold (1 dilution) greater than the minimum required dilut ion if no ADA swere 
detected at baseline (treatment -induced ADA) or those with a 4 -fold (2 dilut ions) increase in t iter 
compared to baseline if ADA s were detected at baseline (treatment-boos ted ADA). For the TE 
ADA+ participants , the di stributi on of  maximum  titers will be described. The frequency of 
neutralizing ant ibodies may also be tabulated in ADA+ participants . 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
4 6 T he rel at i o ns hi p bet wee n t he prese nce of a nt i b o dies t o L Y 3 8 3 2 4 7 9 c o nce ntrati o ns/ P K  
para m eters, a n d/ or safet y assess me nt m a y be assesse d. 
9. 4. 5. Ot her A n al yses 
9. 4. 5. 1. P artici p a nt Dis p ositi o n 
A detaile d descri pti o n o f All p arti ci pa nts w h o di sc o nti n ue fr o m t h e st u d y  will be i d e ntifie d, a n d 
t h e e xte nt of t heir partici pat i o n i n t he st u d y  will be re p orte d. If k n o w n, a reas o n f or t heir 
di sc o nti n uat i o n will  b e gi ve n. 
9. 4. 5. 2. P artici p a nt C h ar acteristics 
Eac h partici pa nt’s baseli ne c haracteristics a n d ot her de m o gra p hic c haracterist ic s w ill be 
rec or de d, liste d, a n d s u m marize d b y  tr e at m e nt gr o u p a n d o verall .
9. 5. I nteri m A n al yses 
T here are n o i nt eri m a nal yses pla n ne d f or t his st u d y .If  a n u n pla n ne d i nteri m a nal ysis is dee me d 
necessar y , t he Lill y C P, C R P/i n vesti gat or, or desi g nee will c o ns u lt  w it h t he a p pr o priate me dical 
di rect or or desi g nee t o deter mi ne if it is necessar y  t o a m e n d t he pr ot oc ol .
F or details o f access t o data d uri n g t he st u d y ,see Secti o n 6. 6. 2 .
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
4710. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be con ducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
International Ethical Gu idelines
Applicable Internat ional Council for Harmonis ation (ICH) good clinical practice (GCP) 
Guidelines , and
Applicable laws and regulations .
The protocol, protocol amendments, ICF, IB, and other relevant documents (e .g., adverti sements) 
must be submi tted to an IRB/IEC by  the invest igator and reviewed and approved by the IRB/IEC 
before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes n ecessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC
Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required by 
IRB/IEC procedures , and
Provi ding oversight of the conduct of the study  at the site and adherence to requirements 
of 21 Code of Federal Regulat ions (CFR ), ICH guidelines, the IRB/IEC, and all other 
applicable local regulat ions.
Study sites are com pensated for parti cipat ion in the study  as detailed in the clinical trial 
agreem ent.
10.1.2. Informed Consent Process
The investigator or theirrepresentative will explain th e nature of the study , incl uding the ri sks 
and benefits, to the parti cipant or theirlegally authori zed representative and answer all quest ions 
regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary.Participants or thei r legally 
authori zed representative will be required to sign a statement of informed consent that meets the 
requi rements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portabilit y and 
Accountabilit y Act requirements, where applicable, and the IRB/IEC or study  center.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
48The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained before 
the participant was enter ed in the study  and the date the written consent was obtained. The 
authori zed person obtaining the informed consent and, if applicable, the individual designated to 
witness a verbal consent, must also sign the ICF.
Parti cipants m ust be re -consented to the most current version of the ICF(s) during their 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  authori zed 
representative and is kept on file .
10.1.3. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records ,datasets
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information thatwould make the participant ident ifiable will not be transferred.
The parti cipant must be informed that theirpersonal study -related data will  be used by  the 
sponsor in accordance wit h local data protecti on law. The l evel of disclosure m ust also be 
explained to the participant who will be required to give consent for their data to be used as 
described in the in formed consent.
The parti cipant must be informed that theirmedical records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authorities.
The sponsor has processes in place to ensure data protection, informat ion securit y,and data 
integrity.These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
10.1.4. Dissemina tion of Clinical Study Data
A clinical study  report will be provided for this study  and a summary  of study  information 
provi ded on publicly  available websi tes.
10.1.5. Data Quality Assurance
Investigator responsibilities
All participant data relat ing to the study  will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e.g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by  physically  or electroni cally 
signing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF. Source data may include laboratory tests, medical records, and 
clinical notes.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct access to source data documents.
Data monitoring and management
The Monitoring Plan includes
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
49monitoring details describing str ategy, for example , risk-based init iatives in operations 
and qualit y such as risk management and mitigation strategi es and analyt ical risk-based 
monitoring 
methods 
responsibilit ies 
requi rements 
handling of nonco mpliance issues ,and 
monitoring techniqu es.
The sponsor or designee is responsible for the data management of this study  including qualit y 
checking o f the data. The sponsor assumes accountabilit y for acti ons del egated to other 
individuals (e .g., contract research organizat ions).
Study  monitors w ill perform ongoing source data verification to confirm that data entered in the 
CRF by authori zed si te personnel are accurate, complete, and verifiable from source documents .
They  will also ensure that the safet y and ri ghts of parti cipants are being prote cted,and that the 
study  is being conducted in accordance wit h the currently approved protocol and any other study  
agreem ents, ICH GCP, and all applicable regulatory  requirements.
Records retention and audits
Records and documents, including signed ICFs, pertaining to the conduct of this study  must be 
retained by the invest igator for the time period outlined in the clinical tri al agreement unless 
local regulati ons or inst itutional po licies require a longer retention period.
No records may be destroy ed during the retention period without the written approval of the 
sponsor. No records may  be transferred to another locat ion or party  without wri tten notificat ion 
to the sponsor.
The sponsor or its representatives will periodically check a sample of the part icipant data 
recorded against source documents at the study site.The study  may be audi ted by the sponsor or 
its representatives, and by regulatory  agencies at any  time.Investi gators will  be given notice 
before an audit occurs.
Data Capture System
The inv estigator i s responsible for ensuring the accuracy , com pleteness, l egibili ty, and timeliness 
of the data reported to the sponsor.
An electronic data capture (EDC) system  will be used in this study  for the collect ion of CRF 
data. The invest igator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system. The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by signing the CRF .
Data collected via the sponsor- provided data capture system swill be stored at third parties .The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
5 0 Data m a na ge d b y  a ce ntral  ve n d or, s uc h as la b orat or y  test data, will be st ore d electr o nicall y  i n 
t h e ce ntral  ve n d or’s data base s yste m a n d re p orts wil l be pr o vi de d t o t he i n vesti gat or f or re vie w 
a n d rete nti o n. Data will s u bse q ue nt l y be tra nsferre d fr o m t h e ce ntral  ve n d or t o t he sp o ns or data 
ware h o use. 
Data fr o m c o m p lai nt f or ms s u b mitte d t o t h e s p o ns or will be e nc o de d a n d st ore d i n t he gl o bal 
pr o d uct c o m plai nt ma na ge me nt s y st e m .
1 0. 1. 6. S o urce D oc u me nts 
S o urce d oc u me nts pr o vi de e vi de nce f or t he e xiste nce of t he partici pa nt a n d s u bsta ntiate t he 
i nt e gri t y  of  t he data c ollecte d. S o urce d oc u me nts are file d at t he i n vest i gat or’s site. 
Data re p orte d o n t he C R F t hat are tra nscri be d fr o m s o urce d oc u me nts m ust be c o nsiste nt wit h 
t h e s o urce d oc u me nts or t he discre pa ncies m ust be e x plai ne d. T he i n vesti gat or ma y  n ee d t o 
re q uest pre vi o us me dical rec or ds or tra nsfer rec or ds, de pe n di n g o n t he st u d y . C urre nt m e dical 
rec or ds m ust be a vaila ble. 
T he defi nit i o n of w hat c o nstit utes s o urce data ca n be f o u n d i n Sect i o n1 0. 1. 5 .
1 0. 1. 7. St u d y a n d Site St art a n d Cl os ure 
T he st u d y  start date is t he date o n w hic h t he cli nical st u d y will be o pe n f or recr uit me nt  of  
parti ci pa nts. 
Site Cl os ure 
T he s p o ns or desi g nee reser ves t he ri g ht t o cl ose t he st u d y si t e or ter mi nate t he st u d y  at a n y  ti me 
f o r a n y  reas o n at t he s ol e discret i o n of t he s p o ns or. St u d y  si t e swill be cl ose d u p o n st u d y  
c o m plet i o n. A st u d y  si te is c o nsi dere d cl ose d w he n all re q uire d d oc u me nts a n d st u d y  s u p plies 
ha ve bee n c o llecte d a n d a st u d y -si t e cl os ure visi t has bee n perf or m e d. 
T he i n vest i gat or ma y i nit iate st u d y -si t e cl os ure at a n y ti me, pr o vi de d t here i s reas o na ble ca use 
a n d e n o u g h n otice is gi ve n i n a d va nce of t he i nte n de d ter mi nat i o n. 
Reas o ns f or t he earl y cl os ure of a st u d y  si te b y t he s p o ns or or i n vesti gat or ma y  i ncl u de b ut are 
n ot li mite d t o 
fail ure of t he i n vest i gat or t o c o m pl y  wi t h  t he pr ot oc ol, t he re q uire me nts of t he I R B/I E C 
or l o c al  h eal t h  a ut h ori ti es, t he s p o ns or ’s pr oce d ures, or G C P g ui deli nes 
ina de q uate recr ui t me nt of parti ci pa nts b y  t he i n vesti gat or , or 
dis c o nti n uat i o n of f urt her st u d y  i nt er ve nt i o n de vel o p m e nt .
If t he st u d y  i s pre m at urel y  ter mi nate d or s us pe n de d, t he s p o ns or s hall pr o m pt l y i nf or m  t he 
in vesti gat ors, t he I E Cs/I R Bs, t he re g ulat or y  a ut h orit ies, a n d a n y c o ntract researc h or ga nizat i o n(s) 
use d i n t he st u d y  of  t he reas o n f or ter mi nat i o n or s us pe nsi o n, as s peci fie d b y t he a p plica ble 
re g ul at or y  r e q ui re me nts. T he in vesti gat or s hall pr o m pt l y i nf or m  t he parti ci pa nts a n d ass ure 
a p pr o priate partici pa nt t h era p y  a n d/ or f oll o w - u p .
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
5110.1.8. Publication Policy
In accordance with the sponsor’s publication po licy, the results of this study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.
10.1.9. Investigator Information
Physicians with a specialt y in infect ious di sease, crit ical care, or pulmo nary disease may
participate as invest igators.
10.1.10. Long -Term Sample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of  the 
intervent ion or af ter the intervent ion beco mes commercially  available.
This table describes the retention period for potential sample t ypes.
Sample Type Custodian Retention Period after Last Pa rticipant Visit
Pharmacogenetics sample Sponsor or designee up to 15 years
Explo ratory  Biomarker Samples Sponsor or designee up to 15 years
Pharmacokinetic (PK) sample Sponsor or designee up to 2 years
Immunogenicity (ADA) sample Sponsor or designee up to 15 years
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
5 2 1 0. 2.  A p pe n di x 2: Cli nic al L a b or at or y Tests 
Cli nical la b orat or y  tests will be perf or me d acc or di n g t o t he S o A. A d dit i o nal details are pr o vi de d 
i n t he f o ll o wi n g ta ble f o r s pecific la b orat or y  t ests .
A d dit i o nal tests ma y be perf or me d at a n y  ti me d uri n g t he st u d y  as deter mi ne d necessar y  b y t he 
i n vesti gat or or re q uire d b y  l ocal re g ulat i o ns. 
Pre g na nc y testi n g will be perf or me d acc or di n g t o t he S o A. 
T he f o ll o wi n g ta bl edescri bes w he n t he l ocal or ce ntral la b orat or y  will  b e use d .
If t he l ocal la b orat or y  res ul ts are use d t o m a ke ei t h er a st u d y  i nt er ve nti o n decisi o n  or res p o nse 
e val uat i o n, t he res ults m ust be rec or de d i nt h e C R F. 
La b orat or y  res ul ts t hat c o ul d u n bli n d t he st u d y  will  n ot be re p orte d t o st u d y site s or ot her bli n de d 
pers o n nel. 
Pr ot oc ol -s pecific re q uire me nts f or i ncl usi o n or e xcl usi o n of partici pa nts are detaile d i n Sect i o n 5
of  t he pr ot oc ol. 
I n vest i gat ors m ust d oc u m e nt t hei r re vie w of eac h la b orat or y  safet y  re p ort. 
Refer t o Secti o n 1 0. 6 f o r rec o m me n de d la b orat or y  t es ti n g f or h y perse nsit i vit y e ve nts. 
Cli nic al L a b or at or y Tests C o m me nts 
He m at ol o g y Assa y e d b y l ocal la b orat or y 
He m o gl o bi n 
He mat ocrit 
Er y t hr oc y te c o u nt ( R B Cs -re d bl o o d cells )
Mea n cell v ol u me 
Mea n cell he m o gl o bi n 
Le u k oc ytes ( W B Cs -w h ite bl o o d cells ) 
Differe ntial 
Ne utr o p hils, se g me nte d 
L y m p h oc ytes 
M o n oc ytes 
E osi n o p hils 
Bas o p hils 
Platelets 
Cell m or p h ol o g y ( R B C a n d W B C) 
Cli nic al C he mistr y Assa y e d b y l ocal la b orat or y 
S o di u m 
P otassi u m 
C hl ori de 
Bicar b o nate 
T otal bilir u bi n 
Direct bilir u bi n Rec or d o n D a y  1 a n d re peat if si g nifica ntl y a b n or mal val ue 
Al kali ne p h os p hatase ( A L P) 
Ala ni ne a mi n otra nsferase ( A L T) 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
53Clinical Laboratory Tests Comments
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT) Record o n Day 1andrepeat if significantly abnormal value
Blood urea nitrogen (BUN)
Creatinine 
Creatine kinase (CK) Record o n Day 1 and repeat if significantly abnormal value
Uric acid Record o n Day 1 and repeat if significantly abnormal value
Total protein
Albumin
Calcium
Phospho rus
Random glucose
Calculations Completed locally
eGFR Calculated by CKD -EPI equation
Hepatitis B surface antigen
Hepatitis B core antibody (HBcAb) 
Hepatitis C antibody
HIV
SARS -Cov-2 viral infection determin ation Local laboratory
  SARS -Cov -2 nasophary ngeal test At screening visit. To be performed only if SARS -CoV -2 point of 
care test is not available
  SARS -Cov-2 point of care On Day-1 if available , and during the study at the investigator’s 
discretio n
SARS-Cov -2 nasal or nasopharyngeal sample 
for research purposesSent to the sponsor for analysis if the SARS -Cov -2 point of care test
performed in parallel is positive
SARS-Cov -2 serology At screening, and then according to schedule o factivities
Urinalysis Assay ed by local laboratory
Specific gravity
pH
Protein
Glucose
Ketones
Bilirubin
Urobilinogen
Blood
Nitrite
Microscopy If dipstick test is abnormal.
Hormones (female) Assay ed by local laboratory.
Serum pregnancy  
Urine pregnancy
Ethanol/drug screening Assay ed by local laboratory.
Urineor breath ethanol screen
Urine drug screen
Pharmacokinetic (PK) Samples Assay ed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
54Clinical Laboratory Tests Comments
Pharmacogenetic sample Assay ed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
Exploratory Biomarker Samples Assay ed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
Serum
Immunogenicity Samples Assay ed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
Anti-LY3832479 antibodies 
Anti-LY3832479 antibodies neutralization
Abbreviations: CKD -EPI=Chronic Kidney Disease Epidemiology Collaboration ; eGFR = estimated glomerular 
filtration rate; HIV = human immunodeficiency virus; SARS -Cov -2 = severe acute respiratory syndrome 
coronavirus 2.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
5510.2.1. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and volumes for all blood 
sampling during the study .
Protocol J2Z- MC-PGAA Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 45 1 45
Clinical laboratory tests a 15 9 135
SARS -CoV -2 serology 10 5 50
Pharmacokinetics (including up to 
5 extra samples if needed)4 11 (16) 44 (64)
Blood discard for cannula patency 1 8 8
Immunogenicity 10 5 50
Pharmacogenetics 3 1 3
Serum for exploratory biomarkers 10 6 60
Total 395 (415 )
Total for clinical purposes (rounded up to the nearest 10 mL ) 400 (420 )
aAdditional samples may be drawn if needed for safety purposes.
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
5 6 1 0. 3. A p pe n di x 3: A d verse E ve nts: Defi niti o ns a n d Pr oce d ures f or 
Rec or di n g, E v al u ati n g, F oll o w -u p, a n d Re p orti n g 
1 0. 3. 1. Defi niti o n of A E 
A E Defi niti o n 
A n A E i s a n y  u nt o w ar d me d ical occ urre nce i n a patie nt or cli nical st u d y part ic i pa nt, 
t e m p orall y  ass o ci at e d wi t h  t he use of st u d y  i nt er ve nt i o n, w het her or n ot c o nsi dere d 
r el ate d t o t he st u d y  i nt er ve nt i o n. 
N O T E: A n A E ca n t heref ore be a n y u nfa v ora ble a n d u ni nte n de d si g n (i ncl u di n g a n 
a b n or m al  l a b orat or y  f i n di n g), s y m pt o m, or disease ( ne w or e xacer bate d) te m p orall y 
ass oci at e d wi t h  t he use of st u d y  i nt er ve nt i o n. 
E ve nts Meeti n g t he A E D efi niti o n 
A n y a b n or mal la b orat or y  test res ul ts ( he mat ol o g y , cli nical c he mistr y , or uri nal ysis) or 
ot her safet y assess me nts (e . g ., E C G, ra di o l o gical sca ns, vital si g n meas ure me nts), 
i ncl u di n g t h ose t hat w orse n fr o m baseli ne, c o nsi dere d cli nicall y si g nifica nt i n t he 
me dical a n d scie nt ific j u d g me nt of t he i n vesti gat or (i . e. , n ot relate d t o pr o gressi o n of 
u n derl yi n g disease). 
E xacer bat i o n of a c hr o nic or i nter mitte nt pre -e xist i n g c o n dit i o n i ncl u di n g eit her a n 
i ncrease i n fre q ue nc y a n d/ or i nte nsit y of  t he c o n di ti o n .
Ne w c o n dit i o ns detecte d or dia g n ose d after st u d y  i nter ve nt i o n a d mi nistrati o n e ve n 
t h o u g h it m a y  h a ve bee n prese nt bef ore t he start of t he st u d y .
Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d dr u g -dr u g i nteracti o n. 
Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d o ver d ose of eit her st u d y  
i nt er ve nt i o n or a c o nc o mita nt  me dicat i o n. O ver d ose per se will n ot be re p orte d as a n 
A E/ S A E u nless it is a n i nte nti o nal o ver d ose ta ke n wit h p ossi ble s uici dal/self -har mi n g 
i nt e nt. S uc h o ver d ose s h o ul d be re p orte d re gar dless of se q uelae. 
E ve nts N O T Meeti n g t he A E D efi niti o n 
A n y cli nicall y  si g nifica nt a b n or mal la b orat or y  f i n di n gs or ot her a b n or mal safet y 
assess me nts t h at are ass ociate d wit h t he u n derl yi n g disease, u nless j u d ge d b y t he 
i n vesti gat or t o be m ore se vere t ha n e x pecte d f or t he partici pa nt’s c o n dit i o n. 
T he disease/ dis or der bei n g st u di e d or e x pecte d pr o gressi o n, si g ns, or s y m pt o m s of t he 
di sease/ dis or der bei n g st u die d, u nless m ore se vere t ha n e x pecte d f or t he partici pa nt’s 
c o n di ti o n. 
Me dical or s ur gical pr oce d ure (e . g. , e n d osc o p y , a p pe n dect o m y): t he c o n dit i o n t hat 
lea ds t o t he pr oce d ure is t he A E. 
Si t u ati o ns i n w hic h a n u nt o war d me dical occ urre nce di d n ot occ ur (s ocial a n d/ or 
c o n ve nie nce a d missi o n t o a h os pital). 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
5 7 A nt ic i pate d da y -t o -da y fl uct uati o ns of pre -e xist i n g disease(s) or c o n dit i o n(s) prese nt or 
detecte d at t he sta rt of t he st u d y  t hat d o n ot w orse n. 
1 0. 3. 2. Defi niti o n of S A E 
If a n e ve nt is n ot a n A E per defi nit i o n a b o ve, t he n it ca n n ot be a n S A E e ve n if seri o us c o n dit i o ns 
are met (e . g ., h os pitalizat i o n f o r si g ns/s y m pt o ms of t he disease u n der st u d y , deat h d ue t o 
pr o gressi o n of disease). 
A n S A E is defi ne d as a n y u nt o w ar d me dic al occ urre nce t h at, at a n y d ose: 
a. Res ults i n de at h 
b. Is life -t hre ate ni n g 
T he ter m  “ life -t h reate ni n g” i n t he defi nit i o n of “s eri o us ”refers t o a n e ve nt i n w hic h t he 
parti ci pa nt was at ri s k of deat h at t he ti me o f t h e e ve nt. It d oes n ot refer t o a n e ve nt, w hic h 
h y p ot heti call y  mi g ht ha ve ca use d deat h, if it were m ore se vere. 
c. Re q uires i n p atie nt h os pit aliz ati o n or pr ol o n g ati o n of e xisti n g h os pit aliz ati o n 
I n ge neral, h os pitalizat i o n si g nifies t hat t he partici pa nt has bee n a d mi tte d t o h os pi t al 
f o r o bser vat i o n a n d/ or treat me nt t hat w o ul d n ot ha ve bee n a p pr o priate i n t he 
p h ysicia n’s office or o ut patie nt setti n g. C o m plicat i o ns t hat occ ur d uri n g h os pi talizati o n 
are A Es. If a c o m plicat i o n pr ol o n gs h os pi talizati o n or f ulfills a n y  ot her seri o us cri t eri a, 
t h e e ve nt is seri o us. W he n i n d o u bt as t o w het her “ h os pitalizati o n” occ urre d or was 
necessar y , t he A E s h o ul d be c o nsi dere d seri o us. 
H os pitalizati o n f o r el ect i ve treat me nt of a pre -e xisti n g c o n dit i o n t hat di d n ot w orse n 
fr o m baseli ne is n ot c o nsi dere d a n A E. 
d. Res ults i n persiste nt dis a bilit y/i nc a p acit y 
T he ter m disa bili t y  m ea ns a s u bsta nt ial disr u pt i o n of a pers o n’s a bilit y t o c o n d uct 
n or m al  lif e f u nc ti o ns. 
T his defi nit i o n is n ot i nte n de d t o i ncl u de e x perie nces of relat i vel y mi n or me dical 
si g nifica nce s uc h as u nc o m p licate d hea dac he, na usea, v o mit i n g, di arr hea, i nfl ue nza, 
a n d acci de ntal tra u ma (e . g ., s prai ne d a n kle) t h at ma y i nt erf ere wi t h  or pre ve nt 
e v er y da y life f u ncti o ns b ut d o n ot c o nstit ute a s u bsta ntial disr u pt i o n. 
e. Is a c o n ge nit al a n o m al y/ birt h defect 
f. Ot her sit u ati o ns: 
Me dical or scie nt ific j u d g me nt s h o ul d be e xercise d i n deci di n g w het her S A E re p orti n g 
is a p pr o priate i n ot her sit uati o ns s uc h as i m p orta nt me dical e ve nts t hat ma y n ot be 
i m me diatel y  life t h reate ni n g or res ult i n deat h or h os pitalizati o n b ut ma y je o par dize t he 
parti ci pa nt or m a y re q ui r e m e dical or s ur gi cal i nter ve nt i o n t o pre ve nt 1of  t he ot her 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
5 8 o utc o m es liste d i n t he a b o ve defi nit i o n. T hese e ve nts s h o ul d us uall y be c o nsi dere d 
seri o us. 
E xa m ples of s uc h e ve nts i ncl u de i n vasi ve or mali g na nt ca ncers, i nte nsi ve treat me nt i n 
a n e mer ge nc y r o o m or at h o me f or aller gic br o nc h os pas m, bl o o d d yscrasias ,or 
c o n v ulsi o ns t hat d o n ot res ult i n h os pit alizat i o n, or de vel o p me nt of dr u g de pe n de nc y or 
dr u g a b use .
1 0. 3. 3. Rec or di n g a n d F oll o w - U p of A E a n d/ or S A E 
A E a n d S A E Rec or di n g 
W he n a n A E/ S A E occ urs, it is t he res p o nsi bilit y of t he i n vesti gat or t o re vie w all 
d oc u m e nt ati o n (e . g ., h os pital pr o gress n otes, la b orat or y  re p orts, a n d di a g n osti cs 
re p orts) relate d t o t he e ve nt. 
T he i n vest i gat or will t he n rec or d all rele va nt A E/ S A E i nf or mat i o n i n t he C R F. 
It i s n ot acce pta ble f or t he i n vest i gat or t o se n d p h ot oc o pies of t he partici pa nt’s me dical 
rec or ds t o t h e s p o ns or or desi g nee i n lie u of c o m pleti o n of t he A E/ S A E C R F pa ge. 
T here m a y be i nsta nces w he n c o pies of me dical rec or ds f or certai n cases are re q ueste d 
b y t h e s p o ns or or desi g nee . I n t his case, all partici pa nt i de ntifiers, wit h t he e xce pt i o n of 
t h e partici pa nt n u m ber, will be re dacte d o n t he c o pies of t he me dical rec or ds bef ore 
s u b missi o n t o t h e s p o ns or or desi g nee .
T he i n vest i gat or will atte m pt t o esta blis h a dia g n osis of t he e ve nt base d o n si g ns, 
s y m pt o ms, a n d/ or ot her cli nical i nf or mat i o n. W he ne ver p ossi ble, t he di a g n osis ( n ot t he 
i n di vi d ual si g ns/s y m pt o ms) will be d oc u me nte d as t he A E/ S A E .
Assess me nt of I nte nsit y 
T he i n vest i gat or will ma ke a n assess me nt of i nte nsit y f o r eac h A E a n d S A E re p orte d d uri n g 
t h e st u d y  a n d assi g n it t o 1 of t he f o ll o wi n g cate g ori es: 
Mil d: A n e ve nt t hat is easil y t olerate d b y t he partici pa nt, ca usi n g mi ni mal disc o mf o rt ,
a n d n ot i nterferi n g wit h e ver y da y act i vit ies. 
M o derate: A n e ve nt t hat ca uses s ufficie nt disc o mf ort a n d i nterferes wit h n or m al  
e ver y da y act i vit ies. 
Se vere: A n e ve nt t h at pre ve nts n or mal e ver y da y acti vi ti es. A n A E t hat is assesse d as 
se vere s h o ul d n ot be c o nf use d wit h a nS A E. Se vere is a cate g or y  utilize d f or rati n g t he 
i nt e nsi t y  of  a n e ve nt; a n d b ot h A Es a n d S A Es ca n be assesse d as se vere. 
A n e ve nt is defi ne d as ‘seri o us’ w he n i t m eets at l east 1 of t he pre defi ne d o utc o mes as 
descri be d i n t he defi nit i o n o f a n S A E, N O T w he n it is rate d as se vere. 
Assess me nt of C a us alit y 
T he i n vest i gat or is o bli gate d t o assess t he relati o ns hi p bet wee n st u d y i nter ve nt i o n a n d 
eac h occ urre nce of eac h A E/ S A E. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
5 9 T he i n vest i gat or will c o nsi der a n y A Es, S A Es, a n d cli nicall y i m p orta nt la b orat or y 
a b n or m ali ti es as relate d t o t he st u d y  i nt er ve nt i o n u nless t here is clear e vi de nce t hat t he 
e ve nt i s n ot rel ate d .
T he i n vest i gat or will use cli nical j u d g me nt t o deter mi ne t he relat i o ns hi p. 
Alt er nat i ve ca uses, s uc h as u n derl yi n g disease(s), c o nc o mita nt t hera p y, a n d ot her ris k 
fact ors, as well as t he te m p oral relati o ns hi p of t he e ve nt t o st u d y  i nt er ve nt i o n 
a d mi nistrati o n will be c o nsi dere d a n d i n vest i ga te d. 
T he i n vest i gat or will als o c o ns ult t he I B a n d/ or Pr o d uct I nf or mati o n, f or mar kete d 
pr o d ucts, i n his/ her assess me nt. 
F or eac h A E/ S A E, t he i n vest i gat or m ust d oc u me nt i n t he me dical n otes t hat he/s he has 
re vie we d t he A E/ S A E a n d has pr o vi de d a n assess me nt of  ca usalit y. 
T here m a y be si t u ati o ns i n w hic h a n S A E has occ urre d a n d t he i n vest i gat or has 
mi ni mal i nf or mat i o n t o i ncl u de i n t he i nit ial re p ort t o t h e s p o ns or or desi g nee . 
H o we ver, it is ver y  i m p orta nt t hat t he i n vest i gat or al wa ys ma ke a n assess me nt of 
ca usalit y f o r e ver y  e v e nt bef ore t he i nit ial tra ns missi o n of t he S A E data t o t h e s p o ns or 
or desi g nee .
T he i n vest i gat or ma y c ha n ge his/ her o pi ni o n of ca usalit y i n li g ht of f o ll o w- u p 
i nf or m at i o n a n d se n d a nS A E f oll o w -u p re p ort wi t h  t he u p date d ca usalit y asse ss me nt. 
T he ca usalit y assess me nt i s 1of  t he cri teria use d w he n deter mi ni n g re g ulat or y  
re p orti n g re q uire me nts. 
F oll o w -u p of A Es a n d S A Es 
T he i n vest i gat or is o bli gate d t o perf or m or arra n ge f or t he c o n d uct of s u p ple me ntal 
meas ure me nts a n d/ or e val uat i o ns as me dicall y i n dicate d or as re q ueste d b y t h e s p o ns or 
or desi g nee t o el uci date t he nat ure a n d/ or ca usalit y of t he A E or S A E as f ull y as 
p oss i ble. T his ma y i ncl u de a d dit i o nal la b orat or y  tests or i n vest i gat i o ns, 
hist o pat h ol o gical e xa mi nat i o ns, or c o ns ultati o n wit h ot her healt h care pr ofessi o nals. 
If a partici pa nt dies d uri n g partici pati o n i n t h e st u d y  or d uri n g a rec o g ni z e d f ol l o w- u p 
p eri o d, t h e i n vest i gat or will pr o vi de t h e s p o ns or or desi g nee wi t h  a c o p y  of  a n y  
p ost m ort e m  f i n di n gs i ncl u di n g hist o pat h ol o g y . 
Ne w or u p date d i nf or mat i o n will be rec or de d i n t he ori gi nall y c o m p lete d C R F. 
T he i n ve st i gat or will s u b mit a n y u p date d S A E data t o t h e s p o ns or or desi g nee wi t hi n 
2 4 h o urs of recei pt of t he i nf or mati o n. 
1 0. 3. 4. Re p orti n g of S A Es 
S A E Re p orti n g vi a P a per C R F 
Facsi mile tra ns missi o n of t he S A E Re p ort is t he preferre d met h o d t o tra ns mit t his 
i nf or m at i o n t o t he s p o ns or or desi g nee. 
I ni ti al  n otificati o n via tele p h o ne d oes n ot re place t he nee d f or t he i n vest i gat or t o 
c o m plete a n d si g n t he S A E Re p ort wit hi n t he desi g nate d re p orti n g ti me fra mes. 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
60Contacts for SAE reporting can be found in the SAE Report .
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
6110.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
10.4.1. Women
Only women of non -childbearing potential may  parti cipate in this study .
Definitions:
Woman of Childbearing Potential
A wo man is considered fertile fo llowing menarche and unt il beco ming postmenopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, additional eval uation shoul d be considered.
Woman Not of Childbearing Potential
Women in the fo llowing categori es are not considered woman of childbearing potential
1.Prem enarchal
2.Prem enopausal  female wi th 1 of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the above, 
(e.g., mullerian agenesis, androgen insensit ivity), investigator discret ion shoul d be applied to 
determining study  entry .
Note: Documentation can come fro m the site personnel’s :review of the participant’s medical 
records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female is defined as, women with
12 m onths of amenorrhea for women >55 years , with no need for follicle -stimulat ing 
horm one ( FSH)
12 m onths of amenorrhea for women >40 years with FSH ≥40 m IU/mL and no other 
medical condit ion such as anorexia nervosa and not taking medicat ions during the 
amenorrhea (e.g. oral contraceptives, hormon es, gonadotropin -releasing horm one, 
anti-estrogens, sel ective estrogen receptor modulators, or chemotherapy that induced 
amenorrhea )
10.4.2. Men
Men, regardl ess of their fertilit y status, m ust agree to ei ther remain abstinent (if this is their 
preferred and usual lifest yle) or use condoms as well as 1 additional hi ghly effective m ethod of 
contraception (less than 1% failure rate) or effect ive method o f contraception with nonpregnant 
wom en of childbearing potential partners for the duration of the study  and unt il their plasma 
concentrations are below the level that could result  in a relevant potential exposure to a possible 
fetus, predicted to be 140 days after the last dose.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
62Men wi th pregnant partners should use condoms during intercourse for the duration of the study  
and until the end of est imated relevant potential exposure to the fetus , predi cted to be 140 days 
after the l ast dose.
Acceptable Methods of Contraception for Female Partners of Male Participants
Highly effect ive method sof contracepti on (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives
implanted con tracepti ves,or 
intrauterine devices . 
Effect ivemethod sof contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges .
Men and their partners may choose to use a double –barrier m ethod of contraception thatmust 
include use of a spermicide .
10.4.3. Collection of Pregna ncy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only to 
male participants who receive study  intervent ion.
After obtaining the necessary  signed informed consent from the pregnant female partner direct ly, 
the invest igator will record pregnancy informat ion on the appropriate form and submit it to the 
sponsor within 24 hours of learning of the partner’s pregnancy.
The female pa rtner will  also be followed up to determine the outcome of the pregnancy.
Inform ation on the status of the mother and child will be forwarded to the sponsor. Generally, the 
follow-up will be no longer than 6 to 8 weeks fo llowing the estimated delivery date . Any 
termination o f the pregnancy  will be reported including fetal status (presence or absence of 
anomalies) andindication for the procedure.
Female participants who become pregnant
The invest igator will co llect pregnancy information on any female partic ipant who becomes 
pregnant while part icipating in this study .The init ial informat ion will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning o f a participant ’s 
pregnancy.
The parti cipant will be fo llowed up to det ermine the outcome of the pregnancy. The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate and the informat ion will be 
forwarded to the sponsor. Generally, fo llow-up will not be required for longer than 6 to 8 weeks 
beyo nd the estimated delivery date. Any terminat ion of pregnancy will be reported, including 
fetal status (presence or absence of ano malies) or indicat ion for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  com plicat ion or 
elective termination o f a pregnancy  for medical  reasons will be reported as an AE or SAE. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
6 3 A s p o nta ne o us a b orti o n ( occ urri n g at < 2 0 wee ks gestati o nal a ge) or still birt h ( occ urri n g at > 2 0 
wee ks gestati o nal a ge) is al wa ys c o nsi dere d t o be a n S A E a n d will be re p orte d as s uc h. 
A n y p ostst u d y  pre g na nc y -relate d S A E c o nsi dere d reas o na bl y  relate d t o t he st u d y  i nt er ve nt i o n b y 
t h e i n vest i gat or will be re p orte d t o t he s p o ns or as descri be d i n Secti o n 8. 3. 4 . W hile t he 
i n vesti gat or is n ot o bli gate d t o acti vel y see k t his i nf or mat i o n i n f o r m er st u d y  p arti ci pa nts, he or 
s he m a y lear n of a n S A E t hr o u g h s p o nta ne o us re p orti n g. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
6 4 1 0. 5. A p pe n di x 5: Ge netics 
S a m ple c ollect i o n i nf or mat i o n is f o u n d i n A p pe n di x 2, Secti o n 1 0. 2 ( Cli nical La b orat or y Tests). 
Ge net ic variat i o n ma y i m pact a partici pa nt’s res p o nse t o st u d y  i nt er ve nt i o n, s usce pt i bilit y t o, a n d 
se verit y a n d pr o gressi o n of  disease. Vari a ble res p o nse t o st u d y  i nt er ve nt i o n ma y be d ue t o 
ge net ic deter mi na nts t hat i m pact dr u g a bs or pti o n, distri b ut i o n, m eta b o lis m, a n d e xcreti o n; 
mec ha nis m o f acti o n of  t he dr u g; di sease et i ol o g y; a n d/ or m ol ec ular s u bt y pe of t he disease bei n g 
treate d. T heref ore, w here l ocal re g ulat i o ns a n d I R B/I E C all o w, a bl o o d sa m ple will be c ollecte d 
f o r D N A a nal ysis fr o m c o nse nti n g part ic i pa nts. 
D N A sa m ples m a y be use d f or researc h relate d t o S A R S -C o V - 2 a n d relate d diseases. T he y ma y 
als o be use d t o de vel o p tests/assa ys i ncl u di n g dia g n ostic tests relate d t o L Y 3 8 3 2 4 7 9 or 
S A R S -C o V - 2 .Ge netic researc h ma y c o nsist of t he a nal ysis o f 1 or m or e ca n di date ge nes or t he 
a nal ysis of ge net ic mar kers t hr o u g h o ut t he ge n o me  as a p pr o priate. 
T he sa m ples ma y  be a nal yze d as part of a m ult ist u d y  assess me nt of ge netic fact ors i n v ol ve d i n 
t h e res p o nse t o L Y 3 8 3 2 4 7 9 or s t u d y  i nt er ve nt i o ns of  t hi s class t o u n der sta n d st u d y  disease or 
r el ate d c o n di ti o ns. 
T he res ults of ge net ic a nal yses ma y be re p orte d i n t he cli nical st u d y  re p ort or i n a se parate st u d y  
s u m mar y. 
T he s p o ns or will st ore t he D N A sa m ples i n a sec ure st ora ge s pace wit h a de q uate meas ures t o 
pr otect c o nfi de nt ia lit y. 
T he sa m ples will be retai ne d at a facilit y selecte d b y t he s p o ns or or its desi g nee w hile researc h 
o n S A R S -C o V - 2 c o nt i n ues b ut n o l o n ger t ha n 1 5 years or ot her peri o d as per l ocal re q uire me nts. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber J 2 Z -M C -P G A A ( c) 
6 5 1 0. 6. A p pe n di x 6: Li ver S afet y: S u g geste d Acti o ns a n d F oll o w -U p 
Assess me nts 
He p atic E v al u ati o n Testi n g 
See Secti o n 8. 2. 4 f o r g ui da nce o n a p pr o priate test select i o n. 
Testi n g will be perf or me d l ocall y .
He m at ol o g y Cli nic al C he mistr y 
H e m o gl o bi n T ot al  bili r u bi n 
H e m at o cri t Di rect bilir u bi n 
Er y t h r o c y tes ( R B Cs -re d bl o o d cells) Al kali ne p h os p hatase ( A L P) 
Le u k oc y tes ( W B Cs -w hite bl o o d cells) Ala ni ne a mi n otra nsferase ( A L T) 
Differe nt ia l: As partate a mi n otra nsferase ( A S T) 
    Ne utr o p hils, se g me nte d Ga m ma -gl uta m yl  tra nsferase ( G G T) 
    L y m p h oc ytes Creati ne ki nase ( C K) 
    M o n oc y t es Ot her C he mistr y 
    Bas o p hils Aceta mi n o p he n 
    E osi n o p hils Aceta mi n o p he n pr otei n a d d ucts 
Pl at el ets Al kali ne p h os p hatase is oe nz y mes 
Cell m or p h o l o g y  ( R B C a n d W B C) Cer ul o pl as mi n 
C o a g ul ati o n C o p per 
Et h yl alc o h o l ( Et O H) 
Pr ot hr o m bi n ti me, I N R ( P T -I N R) Ha pt o gl o bi n 
Ser ol o g y I m m u n o gl o b uli n I g A ( q ua ntitati ve) 
He pati ti s A vi r us ( H A V) testi n g: I m m u n o gl o b uli n I g G ( q ua ntitati ve) 
    H A V t otal a nt i b o d y I m m u n o gl o b uli n I g M ( q ua nt it ati ve) 
    H A V I g M a nti b o d y P h os p hat i d ylet ha n o l ( P Et h) 
He patis B vir us ( H B V) testi n g: Uri ne C he mistr y 
    He patit is B s urface a nt i ge n ( H Bs A g) Dr u g scree n 
    He patit is B s urface a nt i b o d y  (a nt i- H Bs) Et h yl gl uc ur o ni de ( Et G) 
    He patit is B c ore t otal a nt i b o d y  (a nt i- H Bc) Ot her Ser ol o g y 
    He patit is B c ore I g M a nti b o d y A nt i- n uclear a nt i b o d y  ( A N A) 
    He patit is B c ore I g G a nti b o d y A nt i- s m o ot h  m uscle a nti b o d y  ( A S M A) a
    H B V D N A cA nt i- act i n a nt i b o d y  b
He patis C vir us ( H C V) testi n g: E pstei n -Barr vir us ( E B V) testi n g: 
    H C V a nti b o d y     E B V a nti b o d y 
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
66    HCV RNAc    EBV DNAc
Hepati tis D vi rus (HDV) testi ng: Cytomegalovirus (CMV) testing:
    HDV antibody     CMV antibody
Hepati tis E virus (HEV) testing:     CMV DNAc
    HEV IgG antibody Herpes simplex virus (HSV) testing:
    HEV IgM antibody     HSV (Ty pe 1 and 2) ant ibody  
    HEV RNA c     HSV (Ty pe 1 and 2) DNA c
Microbiology Liver ki dney  microsom al type 1 (LKM -1) antibody
Culture:
    Blood
    Urine
aNot required if anti -actin antibody is tested.
bNot required if anti -smooth muscle antibody (ASMA) is tested.
cReflex/confirmation dependent on regulatory requirements, testing availability, or both.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
6710.7. Appendix 7: Recommended Laboratory Testing for Hypersensitivity 
Events
Laboratory  assessments should be performed if the parti cipant experiences generalized urticaria 
or if anaphylaxis is suspected .
Collect sample after the participant has been stabilized, and within 1 to 2 hours of the 
event; however, samples may be obtained as late as 12 hours after the ev ent as analy tes 
can remain altered for an extended period of time. Record the time at which the sample 
was collected.
Obtain a fo llow-up sam ple after approximately  4 weeks.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
68Clinical Lab oratory Tests for Hypersensitivity Events
Hypersensitivity Tests Notes
Selected test may be obtained in the event of anaphylaxis or 
systemic allergic/hypersensitivity reactions.
LY3832479 antidrug 
antibodies 
(immunogenicity/ADA s)Assayed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
LY3832479 concentrations 
(PK)Assayed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
Tryptase Assayed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
The study site should attempt to obtain a tryptase sample within 2 
hours ofthe event . If mor e than 12 hours have passed since the 
event, no tryptase sample should be obtained. If the tryptase sample 
is obtained between 2 and12 hours, or is not obtained, the site 
should collect a urine sample for N -methylhistamine testing. 
Collect the first void urine following the event. Collect a follow -up 
urine sampleafter approximately 4 weeks .
N-methylhistamine Assayed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
Drug -specific IgE Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
Basophil activation test Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
NOTE: The basophil activation test is an in vitro cell -based assay 
that only requires a serum sample. It is a surrogate assay for drug 
specific IgE but is not specifi c for IgE.
Complement (C3, C3a and 
C5a)Assayed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
Cytokine panel Assayed by Lilly -designated laboratory. 
Results will not be provided to the study sites .
Abbreviations: IgE= immunoglobulin E; PK = pharmacokinetic s.
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
6910.8. Appendix 8: Abbreviations
Term Definition
ACE2 angiotensin -converting enzyme 2
ADA antidrug antibody
ADE antibody -dependent enhancement
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
blinding A double -blind study is 1in which neither the participant nor any  of the investigator or 
sponsor personnel who are involved in the treatment or clinical evaluation of the 
participants are aware of the treatment received.
BMI body mass index
BP blood pressure
CFR Code of Federal Regulations
CK creatine kinase
CMV cytomegalovirus
CT computed tomography
Complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
COVID -19 coronavirus disease 2019
CRP clinical research physician: Individual responsible for the medical conduct of the study.
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician ,or other medical officer.
CRU clinical research unit
D. Bil direct bilirubin
EBV Epstein -Barr virus
ECG electrocardiogram
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
70eCRF electronic case report form
EDC electronic data capture
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERCP endoscopic retrograde cholangiopancreatography
FSH follicle -stimulating hormone
GCP good clinical practice
GGT gamma -glutamyltransferase
GLP good laboratory practice
HCV hepatitis C virus
HDV hepatitis D virus
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC independent ethics committee
Ig immunoglobulin
informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by means of a written, signed ,and dated informed consent form .
intervention A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged ) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
INR internatio nal no rmalized ratio
IRB institutional review board
IV intravenous
mAb monoclonal antibody
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
71MRCP magnetic resonance cholangiopancreatography
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PK/PD pharmacokinetics/pharmacodynamics
PT prothrombin time
RBD receptor -binding domain
SAE serious adverse event
SAP statistical analysis plan
SARS -CoV-2 severe acute respiratory syndrome coronavirus 2
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SoA Schedule of Activities
TBL total bilirubin
TCR tissue cross -reactivity
TE treatment emergent
TEAE Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relations hip 
with this treatment.
TK toxicokinetic(s)
ULN upper limit of normal
CONFIDENTIAL Protocol  number J2Z -MC-PGAA (c)
7211. References
Cangelosi RA, Schwartz EJ, Wollkind DJ. A quasi -steady -state approximat ion to the basic 
target -cell-limited viral dynamics model wit h a non -cytopathi c effect. Fron t Microbio l. 
2018;9:54.
Divisio n of AIDS ( DAIDS )table for grading the severit y of adul t and pediatri c adverse events . 
National Inst itute of Allergy and Infectious Diseases. National Inst itutes of Health. US 
Departm ent of Healt h and Human Services. Correcte d version 2.1 .July 2017 . Available at: 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf . Accessed May 19,
2020.
[EMA] European Medicines Agency. Guideline on strategies to ident ify and mit igate ri sks for 
first-in-human and early clinical trials with invest igational medicinal products. 2017. 
Available at: https://www.ema.europa.eu/en/documents/scient ific-guideline/guideline -
strategies -identify -mitigate -risks-first-human -early -clinical -trials-investigational_en.pdf . 
Accessed May  19,2020.
Graham BS. Rapi d COVID -19 vaccine development [published online May 08, 2020]. Science . 
doi: 10.1126/science.abb8923.
Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribut ion of ACE2 protein, the funct ional 
receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol . 
2004;203:631 -637.
Hum an Protein Atlas Project website. Available at:
https://w ww.proteinat las.org/ENSG00000130234- ACE2/t issue. Accessed May  14, 2020 .
Kim KS, Ejima K, Ito Y, et al. Modelling SARS -CoV -2 dynamics: implicat ions for therapy . 
2020. m edRxiv doi : https://doi .org/10.1101/2020.03.23.20040493.
Lieberman P, Nicklas RA, Rando lph C, et al. Anaphylaxis –a practi ce parameter update 2015. 
Ann Allergy Asthma Immunol . 2015; 115:341 -384.
Magyarics Z, Leslie F, Bartko J, et al. Rando mized, double -blind, placebo -controlled, 
singleascending -dose study  of the penetrati on of  a monoclonal antibody  combinat ion 
(ASN100) targeting Staphylococcus aureus cy totoxins in the lung epithelial lining fluid of 
healt hy vo lunteers. Ant imicrob Agents Chemoter. 2019;63(8). pii:e00350 -19.
Simons FER, Ebisawa M, Sanchez -Borges M, et al. 2015 update of the evidence base: World 
Allergy  Organizat ion anaphylaxis guidelines. World Allergy Organ J . 2015;8:32.
Shah Dk, Betts AM. Ant ibody  biodistribut ion coefficients: inferring t issue concentrations of 
monoclonal antibodies based on th e plasma concentrati ons in several preclinical species and 
human. MAbs. 2013;5(2):297 -305.
L e o  D o c u m e n t  I D  =  c 7 3 8 d 4 7 d - 0 3 9 7 - 4 0 8 7 - 9 5 8 0 - 0 7 c e 6 b d 5 e 3 4 9 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 5 - J u l - 2 0 2 0  1 3 : 0 3 : 4 8  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 5 - J u l - 2 0 2 0  1 3 : 1 1 : 4 7  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 